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CLINICAL TRIAL PROTOCOL SYNOPSIS 
Name of company:  
Boehringer Ingelheim 
Name of finished product: 
Metalyse®
Tabulated 
Trial Protocol 
Name of active ingredient:  
Tenecteplase  
 
Protocol date Trial number Planned trial period 
25 September 2007 1123.28 January 2008 – January 2010 
Title of trial: STREAM (STrategic Reperfusion Early After Myocardial Infarction) 
Investigator(s) : Executive Committee: F. Van de Werf (Chairman); P. Armstrong, A. Gershlick (Co-
Chairmen); P. Goldstein, R. Wilcox (additional members) 
Trial site(s) : Multi-national multi-centre trial 
Clinical phase: IIIb-IV 
Objectives: In patients with acute ST-elevation myocardial infarction randomised within 3 hours 
of onset of symptoms the efficacy and safety of a strategy of pre-hospital fibrinolytic 
treatment with tenecteplase and additional antiplatelet and antithrombin therapy 
followed by catheterisation within 6-24 hours or rescue coronary intervention as 
required will be compared to a strategy of primary PCI according to established local 
standards. 
Methodology: Open-label, prospective, randomised, parallel, comparative international multi-centre 
trial 
No. of patients:   
 total: Approximately 2,000 
 each treatment: Approximately 1,000 
Diagnosis and main 
criteria for inclusion: 
Patients with acute ST-segment elevation myocardial infarction randomised within 3 
hours of symptom onset in a pre-hospital setting that cannot reliably undergo primary 
PCI within 60 min of ECG diagnosis 
Inclusion criteria 
1. Age equal or greater than 18 years  
2. Onset of symptoms < 3 hours prior to randomisation 
3. 12-lead ECG indicative of an acute STEMI (ST-elevation will be measured from 
the J point; scale: 1 mm per 0.1 mV): 
≥ 2 mm ST-elevation across 2 contiguous precordial leads (V1-V6) or leads I and 
aVL for a minimum combined total of ≥ 4 mm ST-elevation  
or 
≥ 3 mm ST-elevation in 2 contiguous inferior leads (II, III, aVF) for a minimum 
combined total of ≥ 6 mm ST-elevation    
4. Informed consent received  
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 Exclusion criteria 
1. Expected performance of PCI < 60 minutes from diagnosis (qualifying ECG) or 
inability to arrive at the catheterisation laboratory within 3 hours  
2. Previous CABG 
3. Left bundle branch block or ventricular pacing  
4. Patients with cardiogenic shock - Killip Class 4  
5. Patients with a body weight < 55 kg (known or estimated) 
6. Uncontrolled hypertension, defined as a single blood pressure measurement 
≥ 180/110 mm Hg (systolic BP ≥ 180 mm Hg and/or diastolic BP ≥ 110 mm Hg) 
prior to randomisation  
7. Hospitalisation for cardiac reason within past 48 hours 
8. Recent administration of any i.v. or s.c. anticoagulation within 12 hours, 
including unfractionated heparin, enoxaparin, and/or bivalirudin or current use of 
oral anticoagulation (i.e. warfarin or coumadin) 
9. Active bleeding or known bleeding disorder/diathesis 
10. Known renal insufficiency  
All other standard exclusion criteria for tenecteplase, clopidogrel and enoxaparin.   
Test product(s) : Tenecteplase with concomitant antiplatelet and anticoagulant treatment  
(Group A) 
 Dose and  
 mode of admin. : 
Pre-hospital treatment: 
Tenecteplase 
50 mg of drug reconstituted in 10 ml sterile water for injection given as single 
weight-adjusted i.v. bolus over 5 - 10 seconds 
Weight (kg) Dose (mg)  Dose (ml)
≥55 to <60 30 mg   6 ml 
≥60 to <70 35 mg   7 ml 
≥70 to <80 40 mg   8 ml 
≥80 to <90 45 mg   9 ml 
≥90  50 mg 10 ml 
 
Enoxaparin 
< 75 years:  
- 30 mg i.v. bolus  
- S.c. injections of 1.0 mg/kg every 12 hours until hospital discharge (4 days); the 
first injection should be given within 15 min of the bolus 
- For the first two subcutaneous injections, a maximum of 100 mg should not be 
exceeded 
 
≥ 75 years:  
- No bolus; s.c. injections of 0.75 mg/kg every 12 hours until hospital discharge (4 
days); the first injection should be given immediately 
- For the first two subcutaneous injections, a maximum of 75 mg should not be 
exceeded 
 
For patients of any age with a creatinine clearance < 30 ml/min, s.c. injections of 
1.0 mg/kg will be given in intervals of 24 hours. 
 
Boehringer Ingelheim (Schweiz) GmbH  Final, 25 September 2007 
BI Trial No.: 1123.28 Page 7 of 69 
 Clopidogrel 
< 75 years:  
- 300 mg p.o. loading dose  
- Maintenance dose of 75 mg p.o. once daily 
≥ 75 years:  
- No loading dose; 75 mg p.o. immediately after randomisation  
- Maintenance dose of 75 mg p.o. once daily  
 
Following usage of study drug (until day 4 or discharge, whichever occurs first), the 
maintenance dose of clopidogrel (75 mg p.o. per day) is recommended to be 
continued until day 30 for patients who did not receive a stent, or, if stenting is 
performed, for a longer period according to accepted guidelines. 
 
Additional treatment with acetylsalicylic acid as per local guidelines. 
 
In-hospital treatment: 
- Assessment of reperfusion (by ECG and evaluation of clinical symptoms) 
90 min after injection of tenecteplase or earlier, if clinically indicated 
- Catheterisation: 
- If ST-segment resolution is ≥ 50 % in the qualifying lead (i.e. with maximum 
initial ST-segment elevation in the baseline ECG), diagnostic coronary 
angiography (followed by elective PCI +/- stenting, if indicated) should be 
performed no sooner than 6 hours but within 24 hours after administration of 
tenecteplase (considered as planned catheterisation according to protocol) 
- If ST-segment resolution is < 50 % in the qualifying lead, irrespective of the 
presence or absence of clinical symptoms, rescue coronary intervention should 
be performed promptly  
- In case of haemodynamic or electrical instability or worsening ischaemia 
requiring coronary intervention, urgent coronary intervention is indicated at any 
time (irrespective of previous ST-segment resolution) 
Reference therapy: Standard primary PCI (Group B) 
 dose and  
 mode of admin. : 
Patients randomly assigned to treatment Group B will receive primary PCI according 
to local standards: 
 
Pre-hospital treatment: 
In agreement with international guidelines, upfront antiplatelet and antithrombin 
treatment according to local standards (e.g., acetylsalicylic acid; clopidogrel 300 or 
600 mg; unfractionated heparin/ enoxaparin/ bivalirudin)  
 
In-hospital treatment: 
Standard primary PCI following angiography (additional GP IIb/IIIa antagonists at 
the investigator’s discretion) 
 
Duration of treatment: Not applicable 
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Criteria for efficacy:  Single efficacy endpoints within 30 days: 
- All cause mortality 
- Cardiogenic shock 
- Congestive heart failure 
- Recurrent myocardial infarction 
- Rehospitalisation for cardiac reasons 
- Rehospitalisation for non-cardiac reasons 
 
Single efficacy endpoints at or before discharge: 
- ECG and marker enzyme changes (infarct size; aborted myocardial infarction)  
 
Composite efficacy endpoints within 30 days: 
- Death and shock 
- Death and shock and CHF 
- Death and shock and reinfarction 
- Death and shock and CHF and reinfarction 
 
Criteria for safety: Single safety endpoints within 30 days: 
- Ischaemic stroke 
- Intracranial haemorrhage 
- Non-intracranial bleeds (total, major, minor, and blood transfusions) 
- Serious clinical events (resuscitated ventricular fibrillation, repeat target vessel 
recanalisation) 
 
Composite safety endpoints within 30 days: 
- Total stroke (fatal, disabling, non-disabling) 
- Disabling stroke 
 
Statistical methods: The trial is a hypothesis-generating study to examine a new medical question. No 
confirmatory statistical hypothesis is pre-specified. All statistical tests are of 
exploratory nature based on descriptive p-values for formal statistical hypotheses 
generation. An intent-to-treat analysis of all patients randomised will be carried out. 
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FLOW CHART 
Trial Periods Screening/ 
Baseline 
Randomised 
period End of trial 
Follow-up 
period 
Period 
 
Days 
Pre-hospital 
(incl. ambulance)
1 
In-
hospital
1 to 4 
Hospital 
discharge
or Day 4
Day 30 
 
30 (to 37) 
1-year FUl 
 
365 (to 395) 
Informed consent X  
Demographic data X     
Medical history/current diseases X     
Physical examination X     
Vital signs X     
Concomitant therapy X X X   
Pregnancy test a X     
Haematology b Xb  X   
Renal function c Xc (X)    
Glucose  Xd    
CK/CK-MB and/or Troponin I/T e Xe X    
Twelve-lead ECG X Xf Xf   
Killip class g Xg  Xg   
Inclusion/exclusion criteria X     
Randomisation X     
Administration of trial medication h Xh X    
Catheterisation/PCI i  Xi    
TIMI flow grade  X    
Modified Rankin Scale j    (X)j  
Check for rehospitalisation    X X 
Check for trial endpoints X  
Check for vital status X X 
Check for SAEs/serious clinical 
events l
Xl
 
 
 
a A pregnancy test is required in women of childbearing potential not using a medically accepted method of 
birth control. 
 
b According to hospital practice; but it is required to include at least haemoglobin, haematocrit, erythrocytes, 
leucocytes and platelets pre-hospital or, if not possible, on hospital arrival and before hospital discharge. 
 
c Renal function: A laboratory test of serum creatinine clearance (as per Cockcroft-Gault formula) should be 
done at the first occasion to rule out renal insufficiency or, if applicable, to adapt the dose of subcutaneous 
enoxaparin according to protocol in Group A patients with low creatinine clearance. 
 
d Blood glucose: The first in-hospital fasting value within 24 hours after randomisation should be recorded. 
 
e Cardiac enzymes: The first available value (pre-hospital or upon arrival at hospital) should be recorded. 
Additional values should be taken 8-12 hours and 24 hours after randomisation. Cardiac enzymes should also be 
taken in case of signs and symptoms suggestive of recurrent myocardial ischaemia or reinfarction until day 30. 
 
f Group A: In the receiving hospital an ECG will be recorded 90 min after injection of tenecteplase or earlier, if 
clinically indicated, for assessment of ST resolution. If planned catheterisation or rescue or urgent PCI is done, 
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ECGs will be taken immediately before the procedure and 30 min after the end of the procedure, respectively.  
 
Group B: In the receiving hospital an ECG will be taken prior to the PCI procedure and 30 min after the end of 
the procedure.   
 
For Groups A and B, in addition to baseline and in-hospital ECGs, further ECGs will be recorded before 
hospital discharge or on day 4, whichever occurs first. Serial ECGs should be taken in case of symptoms of 
recurrent ischaemia or reinfarction. ECGs will be centrally adjudicated. 
 
g Killip class will be determined prior to randomisation (or, if this is not possible, immediately on hospital 
arrival) and on the day of discharge or day 4, whichever occurs first. 
 
h Patients randomised to Group A will receive the trial medication on site immediately after randomisation. 
Patients randomised to Group B will receive medication on site and/or prior to primary PCI according to the 
local hospital standards. Medication will be continued as per protocol (Group A) or local standards (B). 
 
i In Group A catheterisation and PCI should be delayed for at least 6 hours, but no longer than 24 hours after 
randomisation, if ST resolution is ≥ 50% and no rescue or urgent PCI is indicated (for details refer to section 
6.2.2.1); whereas in Group B all patients are expected to receive catheterisation and PCI according to local 
standards. Catheterisation and PCI data will be recorded in the eCRF (cf. section 6.2.2.2). 
 
j For patients with non-fatal stroke the Modified Rankin Scale should be determined at day 30. 
 
k Serious clinical events will be recorded until and including day 30. 
 
l If a physical visit is not possible, the assessments may be performed via phone. 
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1. INTRODUCTION 
1.1 MEDICAL BACKGROUND 
The use of timely primary percutaneous coronary intervention (PCI) in patients with ST-
segment elevation myocardial infarction is recommended by guidelines of the European 
Society of Cardiology (ESC) (1) and American College of Cardiology (ACC)/American 
Heart Association (AHA) (2) and has steadily increased during the last years. There is strong 
evidence that primary PCI is an effective therapy for STEMI (3, 4).  
To be efficacious PCI must be provided in an expert and timely fashion. This capacity is not 
equally accessible for all STEMI patients; moreover the frequency of primary PCI use differs 
between countries and even between and within hospitals in the same country.  
Fibrinolysis is a well-accepted, evidence-based and guideline-supported strategy (1, 2, 5), 
especially in patients presenting soon after symptom onset, i.e. within 3 hours (6, 7, 8, 9).  
Pre-hospital fibrinolysis has proven to be feasible in various countries and patient’s manage-
ment organisations, to increase the proportion of patients treated early and improve outcome 
(6, 7, 10, 11, 12, 13). 
In contemporary practice patients receiving fibrinolytic therapy may subsequently be treated 
with PCI either i) as part of a routine angiographic assessment before hospital discharge, ii) 
as a rescue strategy based on inadequate pharmacologic reperfusion, or iii) because of 
spontaneous or provoked recurrent ischaemia. Fibrinolysis combined with subsequent PCI 
has therefore been investigated in several contexts in recent trials (8, 11, 14, 15). 
The concept of “facilitated PCI” with full dose fibrinolysis followed by immediate mandatory 
PCI was not supported by the ASSENT 4 PCI trial – in which patients received either 
primary PCI or TNK followed by PCI (with an average time delay of 104 min) (16). 
However, in a post-hoc subgroup analysis, 90 day mortality was lower for the subgroup of 
patients receiving pre-hospital fibrinolysis followed by PCI (3.1 %) as compared to patients 
receiving primary PCI (4.1 %). This finding is consistent with data from the CAPTIM and 
WEST trials (6, 11), and by data from the French USIC 2000 (9) and FAST-MI (45) 
registries.  
The REACT trial demonstrated that rescue PCI is the best option in patients without > 50 % 
ST resolution at 90 minutes after fibrinolysis. Significantly better event-free survival after 6 
months was shown in patients receiving rescue PCI after failed fibrinolysis as compared to 
those receiving repeated fibrinolysis or conservative therapy (15.3 % vs. 31.0 % vs. 29.8 %, 
respectively). Furthermore, the mortality rate (overall mortality as well as from cardiac 
causes) was lower in the rescue PCI group vs. conservative therapy or repeated fibrinolysis 
(15). Two subsequent meta-analyses support the concept of rescue PCI (17, 18). Recent 
results from the Gracia 2 study also showed better myocardial reperfusion after early routine 
post-fibrinolysis angioplasty and equivalent results on left ventricular function as compared 
to primary PCI (8).  
Recently two large registries were published that also provide data on the outcome of 
fibrinolysis versus primary PCI: In the large Swedish observational cohort study RIKS-HIA 
primary PCI was associated with lower mortality when compared to pre-hospital and in-
hospital fibrinolysis. This difference was less pronounced when time to reperfusion was up to 
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two hours (3.8 % vs. 5.6 % vs. 8.6 % at 30 days, respectively), but increased for a time to 
reperfusion of more than 2 hours (19). Although this reflects the real-life setting in a large 
number of patients, the patient cohort was neither selected nor randomised and the group 
sizes differed highly (with 7,084 vs. 3,078 vs. 16,043 patients, respectively). Interestingly, 
47.3 % of the patients receiving pre-hospital fibrinolysis had PCI or CABG within the 
following 14 days, more than the half of which had rescue PCI on the day of admission. 
Unfortunately subgroup results on mortality were not presented (19).  
In contrast, the publication on a study population of 192,509 patients from the US National 
Registry of Myocardial Infarction (NRMI) demonstrated that with increasing ‘PCI-related 
delay’ (defined as door-to-balloon time minus door-to needle time) the mortality advantage of 
primary PCI over fibrinolysis decreases (20). Furthermore, patient characteristics such as age 
(below or over 65), infarct location (anterior or non-anterior) and pre-hospital delay (up to or 
more than 120 min) have an important influence on the PCI-related delay at which mortality 
rates of both strategies are equal (equipoise). This indicates that, for certain patient popu-
lations, fibrinolytic therapy seems to be equal to or, for PCI-related delay beyond equipoise, 
even better than primary PCI. 
In view of i) these inconsistent data from large registries and rather small clinical trials from 
only a few countries, ii) the challenges in achieving timely expert primary PCI, and iii) new 
knowledge that favourably affects the achievement and maintenance of high quality reperfu-
sion for both pharmacologic and catheter-based strategies, a larger multinational prospective 
clinical trial is needed to evaluate whether fibrinolytic treatment followed by timely cathe-
terisation or rescue coronary intervention in patients presenting early after symptom onset 
represents a desirable alternative strategy to primary PCI.  
1.2 DRUG PROFILE 
Tenecteplase 
Tenecteplase is a derivative of the wild-type tissue type plasminogen activator, tPA (identical 
to the recombinant marketed agent, rtPA, alteplase) with three amino acid site substitutions:  
a threonine (T) replaced by an asparagine, which adds a glycosylation site to position 103;  
an asparagine (N) replaced by a glutamine, thereby removing a glycosylation site from 
position 117;   
and four amino acids, lysine (K), histidine (H), arginine (R), and arginine (R), replaced by 
four alanines at the third site.  
These substitutions prolong half-life, increase fibrin specificity, and increase resistance to 
inhibition by plasminogen activator inhibitor-1 (PAI-1) (21). In pharmacokinetic studies in 
patients with acute myocardial infarction, tenecteplase was shown to exhibit biphasic 
disposition kinetics with an initial half-life of 17-24 min and a terminal half-life of 65-132 
min. The initial half-life accounted for approximately 70 % of the AUC (area under the 
curve) (22).  
In the Thrombolysis in Myocardial Infarction (TIMI) 10A trial, a phase I study with 113 
patients, the prolonged half-life of tenecteplase made its administration as a single IV bolus 
possible (23). Thus, in all subsequent trials tenecteplase was given as a single IV bolus over 5 
-10 seconds. In the TIMI 10B trial, an angiographic phase II study with 886 patients, 
tenecteplase was demonstrated to produce similar patency and TIMI flow as alteplase (Tables 
Boehringer Ingelheim (Schweiz) GmbH  Final, 25 September 2007 
BI Trial No.: 1123.28 Page 18 of 69 
1 and 2) (24). 
Table 1: TIMI Flow and TIMI frame count at 60 minutes, TIMI-10B Study (24) 
Drug/dose 60 min TIMI flow 
grade 2 and 3 
60 min TIMI flow 
grade 3 
60 min corrected 
median TIMI frame count (n) 
Tenecteplase 30 mg (n=176) 79 % 49 % 37 
Tenecteplase 40 mg (n=84) 75 % 55 % 34 
Tenecteplase 50 mg (n=42) 79 % 45 % 37 
tPA (n=165) 78 % 48 % 40 
 
Table 2: TIMI flow grades and median TIMI frame counts at 90 minutes, TIMI-10B Study 
(24) 
Drug and dose 90 min TIMI flow  
grade 2 and 3 
90 min TIMI flow 
grade 3 
90 min corrected  
median TIMI frame count (n) 
Tenecteplase 30 mg (n=297) 77 % 54 % 38 
Tenecteplase 40 mg (n=131) 79 % 63 % 32 
Tenecteplase 50 mg (n=76) 88 % 66 % 34 
tPA (n=303) 82 % 63 % 34 
 
Of all thrombolytic agents tested in large trials, tenecteplase has the highest specificity to 
fibrin. In the TIMI 10 B trial systemic fibrinogen levels in patients treated with tenecteplase 
decreased by only 5-10 % over the first 6 hours after treatment with plasminogen levels 
decreasing by only 10-15 % during the same time period. 
The phase III ASSENT 2 mega-trial demonstrated clinical equivalence of tenecteplase and 
alteplase regarding mortality and ICH rate in 16,949 STEMI patients, whereas tenecteplase 
caused less extracranial major bleeds than alteplase (25). 
ASSENT 3, a large international phase III study with 6,095 patients, compared the efficacy 
and safety of various treatment regimens combining tenecteplase with different antithrombin 
agents: unfractionated heparin (UFH) or enoxaparin or UFH plus abciximab (26). 
Tenecteplase combined with body weight-adjusted UFH showed the same 30-day mortality 
as in ASSENT 2 (6.0 % and 6.2 %, respectively), whereas major bleeds (other than ICH) 
were reduced by half compared to ASSENT 2 (2.2 % and 4.7 %, respectively) (25, 26). The 
reduced bleeding rate without reducing efficacy (27) was probably due to the use of a body 
weight-adjusted and thus probably lower dose of UFH than in ASSENT 2 in accordance with 
the current ACC/AHA (2) and ESC guidelines (1). Although there was no difference in 
mortality between the three treatment groups, adjunctive therapy with abciximab or 
enoxaparin with half-dose tenecteplase reduced ischaemic complications (in-hospital 
reinfarction or ischaemia) as compared to adjunctive treatment with UFH. Particularly for 
abciximab and, to a lesser extent, for enoxaparin, these benefits were obtained at the cost of 
an increased rate of extracranial and intracranial bleeding complications particularly in 
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female and the elderly patients (26). 
In the ASSENT-4 PCI trial patients with STEMI were randomly assigned to either primary 
PCI or PCI preceded by treatment with full-dose tenecteplase, following initial treatment with 
acetylsalicylic acid and single UFH bolus in both groups. Due to higher in-hospital mortality 
in the tenecteplase group (6 % vs. 3 % in the primary PCI group) the trial was stopped after 
1,667 of 4,000 planned patients had been included. The primary endpoint of death, conges-
tive heart failure or shock within 90 days was more frequent in the tenecteplase group (19 % 
vs. 13 %) and more strokes were reported in the tenecteplase group, but major non-cerebral 
bleedings were comparable to the primary PCI group. However, in a post-hoc analysis, the 
mortality at 90 days was lowest in patients receiving tenecteplase-facilitated PCI in the 
ambulance (3.1% vs. 4.1 % for primary PCI) (16). 
Enoxaparin 
Addition of unfractionated or low molecular weight heparin (LMWH) to fibrinolytic therapy 
has been shown to reduce mortality and the rate of recurrent myocardial infarction (26, 28). 
Enoxaparin is a low molecular weight heparin used for anticoagulation that – in contrast to 
heparin which requires intravenous use – can be administered subcutaneously.  
ASSENT 3 Plus, a satellite study of ASSENT 3, investigated the combination of either UFH 
or enoxaparin with tenecteplase in the pre-hospital setting in 1,639 patients (10). Pre-hospital 
treatment increased the proportion of patients treated within 2 hours of symptom onset as 
compared to ASSENT 3 (26). Adjunctive therapy with enoxaparin in ASSENT 3 Plus 
patients presenting higher risk baseline characteristics resulted in a similar mortality as 
compared to ASSENT 3 suggesting that the time to treatment saved in ASSENT 3 Plus (as 
compared to the in-hospital setting in ASSENT 3) was of clinical importance. The rates of 
ICH, total stroke and major bleeds and their age and sex distribution were also similar in the 
two studies and did not show any significant treatment interaction. However, elderly patients, 
in particular women over 75 years, had a higher risk of developing ICH when receiving 
enoxaparin as adjunctive treatment, therefore dose adjustment was recommended (10, 29, 
30).  
Regarding PCI after fibrinolysis and administration of adjunctive heparin or enoxaparin, 30 
day mortality data of the ASSENT 3 Plus trial indicate a similar or slightly reduced mortality 
rate for elective and urgent PCI, respectively, when patients were enrolled less than 3 hours 
from symptom onset.  
Table 3: Mortality at 30 days from the ASSENT 3 Plus study for early patients receiving 
coronary intervention (unpublished results from post-hoc analysis) 
 
 
Type of heparin used 
< 3hrs  
+ urgent PCI 
< 3hrs  
+ elective PCI 
< 3hrs  
+ urgent/elective PCI 
Unfractionated heparin 4.8 % (9/186) 0 % (0/130) 2.9 % (9/316) 
Enoxaparin 4.2 % (7/165) 0 % (0/139) 2.3 % (7/304) 
In the ExTRACT-TIMI 25 trial enoxaparin and UFH were compared as adjunctive therapies 
to fibrinolytic treatment in 20,506 patients with STEMI. This trial used reduced enoxaparin 
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doses in the elderly and the renal insufficiency patient as compared to ASSENT 3 and 
ASSENT 3 Plus (28). In the enoxaparin group the primary end point, death or nonfatal 
myocardial infarction within 30 days, was significantly reduced by 2.1 percentage points 
(17 % relative change) as compared to unfractionated heparin. However, the rate of major 
bleedings was significantly increased in the enoxaparin group (2.1 % vs. 1.4 %), whereas the 
rate of intracranial haemorrhage did not differ significantly at 30 days (28). 
Clopidogrel 
Addition of clopidogrel, a thienopyridine acting as adenosine diphosphate receptor anta-
gonist, to a regimen of fibrinolytic agent, heparin (if indicated), and acetylsalicylic acid lead 
to a highly significant reduction (15.0 % vs. 21.7 % as compared to placebo) in the composite 
endpoint (TIMI flow 0-1 on angiogram, death and recurrent myocardial infarction prior to 
angiography) in the CLARITY study with 3,491 patients presenting with STEMI within 12 
hours from symptom onset. Although mortality was not reduced by addition of clopidogrel as 
compared to placebo, consistent effects of clopidogrel in improving angiographic outcomes 
and reduction of ischaemic events as well as a near-significant (p = 0.052) reduction of the 
stroke risk were observed (31). In addition, the dose used (300 mg loading dose, followed by 
75 mg daily) did not increase the risk of bleeding and was therefore considered safe for 
patients up to 75 years. 
These results are supported by the COMMIT trial, a large study with 45,852 patients admitted 
within 24 hours of symptom onset of myocardial infarction, which showed a highly signifi-
cant proportional reduction of the composite of death, reinfarction, or stroke (32). Although, 
in contrast to CLARITY, no loading dose was given, the mortality rate was reduced signifi-
cantly as compared to placebo. Furthermore, the daily dose of 75 mg neither lead to increased 
bleeding rates in elderly patients (> 70 years of age) nor in patients who received additional 
fibrinolytic treatment (approximately 54 %) (32).  
1.3 RATIONALE FOR PERFORMING THE TRIAL 
Recent data indicate that the patient baseline characteristics (20) and the ‘PCI-related delay’ 
(20, 33) are key factors for the selection of optimal treatment for patients with ST-elevation 
myocardial infarction, i.e. whether fibrinolytic therapy or primary PCI is the more favourable 
treatment strategy for the patient. Local and logistic factors like availability of and distance to 
catheterisation laboratories have a major impact on the PCI-related delay (37), and also 
trigger the decision on treatment selection. A flexible approach, such as alluded to in the 
ACC/AHA guidelines (2), which retains the ability to employ either strategy, is therefore 
desirable. 
As compared to primary PCI, fibrinolytic treatment is a therapy that is immediately available 
and requires much less technical effort and equipment. It has been shown to be beneficial and 
most effective, when it is administered early after onset of symptoms (6, 7, 20, 34). Initiation 
of fibrinolytic treatment within the first three hours after onset of symptoms was shown to 
result in a lower or at least equivalent mortality rate for patients receiving fibrinolytic therapy 
as compared to primary PCI (6, 7, 34). The use of early fibrinolytic treatment in the pre-
hospital setting lead to reduced mortality as demonstrated in different national registries (7, 9, 
12). Further combination with subsequent routine or rescue coronary intervention as required 
has also been supported by recent studies (8, 11, 14, 15, 17).  
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However, a large prospective randomised multi-centre trial comparing pre-hospital fibrino-
lysis with primary PCI in patients presenting early has not been performed and there is a lack 
of data from international clinical trials with patients receiving early fibrinolysis in the pre-
hospital setting.  
The current trial will therefore evaluate the safety and efficacy of a treatment strategy 
designed to reflect optimal clinical practice that includes pre-hospital fibrinolysis and appro-
priate contemporary adjunctive medical therapy followed by coronary intervention, as 
required (‘lyse now, stent later’) ( ), or primary PCI with adequate medical therapy in 
patients with STEMI presenting less than 3 hours after symptom onset.  
35
1.4 BENEFIT / RISK ASSESSMENT 
Patients randomised to Group A will receive tenecteplase combined with antiplatelet (acetyl-
salicylic acid, clopidogrel) and antithrombin (enoxaparin) treatment, and will undergo 
catheterisation within 6-24 hours or rescue coronary intervention as required and, if indicated, 
stent implantation.  
As indicated before, fibrinolysis is a well-established treatment recommended by clinical 
guidelines. The main risk associated with fibrinolytic treatment is bleeding. Patients will be 
carefully screened to minimise bleeding risk. In elderly patients, who are known to have an 
increased bleeding risk (36), the initial loading dose of clopidogrel as well as the initial bolus 
of enoxaparin will be omitted to conform to the evidence-based strategy of the COMMIT and 
ExTRACT trials (28, 30, 32) which support this approach as safe and effective (please refer 
to section 1.2 and 4.1.3). In addition, patients with low body weight (i.e. below 55 kg) will be 
excluded to minimise the small but definitive risk of ICH noted from prior trials. Insufficient 
reperfusion or vessel reocclusion after fibrinolysis will be addressed, as per current 
guidelines, by measuring ST-segment resolution. Patients who do not show evidence of 
adequate reperfusion 90 min after fibrinolysis will undergo prompt rescue PCI.  
Patients randomised to Group B will receive primary PCI, which is a routine treatment in 
patients with ST-elevation acute myocardial infarction (STEMI) and will therefore be used as 
standard treatment in Group B. It has been shown to be safe and effective in securing and 
maintaining coronary artery patency. Patients with contraindications will be excluded. 
Recommendations for adjunctive pharmacologic treatment will be provided. 
During the course of the trial a Data Safety Monitoring Board (DSMB) will review, on a 
regular basis and whenever necessary, all safety data and evaluate the patients’ safety and 
possible risks. The DSMB is entitled to recommend any measures required to secure the 
patients’ safety (cf. sections 7.3.3 and 8.10 for more detail).   
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2. TRIAL OBJECTIVES 
2.1 GENERAL AIM / PRIMARY OBJECTIVE 
This study aims at evaluating, in a proof of concept approach, the outcome of pre-hospital 
patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom 
onset. Following randomisation a strategy of early (pre-hospital) tenecteplase and additional 
antiplatelet and antithrombin therapy followed by catheterisation within 6-24 hours with 
timely coronary intervention as appropriate (or by rescue coronary intervention if required) in 
Group A will be compared to primary PCI performed according to local standards in Group 
B. 
The study is exploratory in nature and will examine this medical question. The efficacy and 
safety endpoints as well as mixed (efficacy and safety) composite endpoints up to or before 
30 days following randomisation will be evaluated.  
All clinical endpoints of main interest will be assessed as single or composite endpoints for 
evaluation of the trial objective. All statistical tests are of exploratory nature based on 
descriptive p-values for formal statistical hypotheses generation. 
2.2 EFFICACY ENDPOINTS 
The following observations are considered as endpoints evaluating the efficacy and will be 
assessed within the intervals indicated respectively. 
2.2.1 Single efficacy endpoints within 30 days 
- All cause mortality 
- Cardiogenic shock 
- Congestive heart failure (CHF) 
- Recurrent myocardial infarction (reinfarction) 
- Rehospitalisation for cardiac reasons 
- Rehospitalisation for non-cardiac reasons 
 
2.2.2 Single efficacy endpoints at or before discharge  
- ECG and enzyme changes (infarct size; aborted myocardial infarction)  
 
2.2.3 Composite efficacy endpoints within 30 days 
- Death and shock 
- Death and shock and CHF 
- Death and shock and reinfarction 
- Death and shock and CHF and reinfarction 
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2.3 SAFETY ENDPOINTS 
The following observations are considered as endpoints evaluating the safety and will be 
assessed at 30 days, respectively. 
 
2.3.1 Single safety endpoints within 30 days 
- Ischaemic stroke 
- Intracranial haemorrhage 
- Non-intracranial bleeds (total, major, minor, and blood transfusions) 
- Serious clinical events (resuscitated ventricular fibrillation, repeat target vessel 
recanalisation) 
 
2.3.2 Composite safety endpoints within 30 days 
- Total stroke (fatal, disabling, non-disabling) 
- Disabling stroke 
 
2.4 MIXED (EFFICACY AND SAFETY) COMPOSITE ENDPOINTS WITHIN 
30 DAYS 
- Death and non-fatal stroke 
- Death and shock and CHF and reinfarction and disabling stroke 
 
2.5 OTHER EVALUATIONS 
2.5.1 Evaluations within 30 days 
- Duration of stay in CCU/ICU  
- Duration of initial stay in hospital  
- Duration of rehospitalisation started until and including day 30 
- Coronary perfusion pre-/post-PCI  
 
2.5.2 Evaluations at 1 year  
- All-cause mortality 
- Rehospitalisation (cause of rehospitalisation) 
 
2.5.3 Evaluations specific for Group A  
- ST resolution 90 min after injection of tenecteplase 
- Incidence of aborted myocardial infarction 
- Need for rescue PCI/revascularisation (as determined by investigator)  
- Need for rescue PCI/revascularisation (centrally adjudicated)  
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3. DESCRIPTION OF DESIGN AND TRIAL POPULATION 
3.1 OVERALL TRIAL DESIGN AND PLAN - DESCRIPTION 
The current trial is designed as an open-label, prospective, randomised, parallel, comparative 
international multi-centre trial.  
In patients with acute ST-elevation myocardial infarction randomised within 3 hours of onset 
of symptoms the efficacy and safety of a strategy of pre-hospital fibrinolytic treatment with 
tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation 
within 6-24 hours or rescue coronary intervention as required will be compared to a strategy 
of primary PCI according to established local standards.  
The trial is of exploratory nature with the aim to examine the potential benefits of this 
medical strategy. Therefore, no confirmatory statistical hypothesis is pre-specified. All 
statistical tests are of exploratory nature based on descriptive p-values for formal statistical 
hypotheses generation. An intent-to-treat analysis of all patients randomised will be carried 
out. 
3.2 DISCUSSION OF TRIAL DESIGN, INCLUDING THE CHOICE OF 
CONTROL GROUP(S) 
Although several studies and registries have compared fibrinolytic treatment with primary 
PCI in patients with acute myocardial infarction, limited trial data are available regarding the 
strategy of early fibrinolysis followed by PCI versus a strategy of primary PCI, in particular 
in the pre-hospital setting (6, 11, 16). Due in part to this lack of data, an exploratory trial 
design was chosen. 
The comparisons of interest are:  
• Group A: fibrinolytic treatment with tenecteplase followed by followed by catheteri-
sation within 6-24 hours or rescue coronary intervention as required.  
vs. 
• Group B: primary PCI according to local standards. 
The comparison will be based on the differences and their 95 % (two-sided) confidence 
intervals (CI) for all clinical endpoints. Should a difference appear in at least one endpoint, 
i.e. the corresponding CI excludes 0 (no difference), and if there is also consistency for the 
other endpoints, then this will be considered evidence for a clinically meaningful difference 
between treatments.  
Should no difference be apparent, the CI will be examined to determine whether a worse 
outcome can be excluded. The exclusion of 1 to 2 % absolute higher incidence (depending on 
the clinical endpoint under consideration) will be considered to indicate comparability, 
depending on the consistency with other clinical endpoints. 
3.3 SELECTION OF TRIAL POPULATION 
Patients with ST-elevation acute myocardial infarction (STEMI) within 3 hours of symptom 
onset in the pre-hospital setting will be randomised to Group A for a strategy of early pre-
Boehringer Ingelheim (Schweiz) GmbH  Final, 25 September 2007 
BI Trial No.: 1123.28 Page 25 of 69 
hospital fibrinolysis or to Group B for a strategy of primary PCI, if the eligibility criteria 
mentioned below are met.  
Approximately 2,000 patients (1,000 patients per group) will be enrolled in approximately 
100-200 sites located in Europe, Canada and other countries.  
3.3.1 Inclusion criteria 
1. Age equal or greater than 18 years  
2. Onset of symptoms < 3 hours prior to randomisation 
3. 12-lead ECG indicative of an acute STEMI (ST-elevation will be measured from the J 
point; scale: 1 mm per 0.1 mV): 
- ≥ 2 mm ST-elevation across 2 contiguous precordial leads (V1-V6) or leads I and 
aVL for a minimum combined total of ≥ 4 mm ST-elevation   
or 
- ≥ 3 mm ST-elevation in 2 contiguous inferior leads (II, III, aVF) for a minimum 
combined total of ≥ 6 mm ST-elevation    
4. Informed consent received  
3.3.2 Exclusion criteria 
1. Expected performance of PCI < 60 minutes from diagnosis (qualifying ECG) or inability 
to arrive at the catheterisation laboratory within 3 hours  
2. Previous CABG  
3. Left bundle branch block or ventricular pacing  
4. Patients with cardiogenic shock - Killip Class 4  
5. Patients with a body weight < 55 kg (known or estimated) 
6. Uncontrolled hypertension, defined as a single blood pressure measurement ≥ 180/110 
mm Hg (systolic BP ≥ 180 mm Hg and/or diastolic BP ≥ 110 mm Hg) prior to 
randomisation  
7. Hospitalisation for cardiac reason within past 48 hours 
8. Recent administration of any i.v. or s.c. anticoagulation within 12 hours including 
unfractionated heparin, enoxaparin and/or bivalirudin or current use of oral anti-
coagulation (warfarin or coumadin) 
9. Active bleeding or known bleeding disorder/diathesis 
10. Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or 
spinal surgery) or recent trauma to the head or cranium (i.e. < 3 months) 
11. Major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2 
months (this includes any trauma associated with the current myocardial infarction) 
12. Any known history of haemorrhagic stroke, ischaemic stroke or transient ischaemic 
attack (TIA), or stroke of unknown origin 
13. Prolonged or traumatic cardiopulmonary resuscitation (> 10 minutes) within the past 2 
weeks 
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14. Known acute pericarditis and/or subacute bacterial endocarditis 
15. Known acute pancreatitis or known severe hepatic dysfunction, including hepatic failure, 
cirrhosis, portal hypertension (oesophageal varices) and active hepatitis  
16. Chronic dialysis or known renal insufficiency  
17. Clinical diagnosis associated with increased risk of bleeding including known active 
peptic ulceration and/or neoplasm with increased bleeding risk 
18. Arterial aneurysm and known arterial/venous malformation  
19. Pregnancy or lactation or parturition within the previous 30 days; women of childbearing 
potential must have a negative urine pregnancy test, or use a medically accepted method 
of birth control 
20. Previous enrolment in this study or treatment with an investigational drug or device 
under another study protocol in the past 7 days 
21. Known hypersensitivity to tenecteplase, alteplase, acetylsalicylic acid, clopidogrel, 
enoxaparin, or to any of the excipients or to the contrast media used in angiography 
22. Inability to follow the protocol and comply with follow-up requirements or any other 
reason that the investigator feels would place the patient at increased risk if the 
investigational therapy is initiated 
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4. TREATMENTS 
4.1 TREATMENTS TO BE ADMINISTERED 
4.1.1 Identity of investigational product(s) 
Tenecteplase (Metalyse®) manufactured by Boehringer Ingelheim, will be provided as 50 mg 
sterile, lyophilized powder in a vial for reconstitution with a 10 ml pre-filled syringe of sterile 
water for i.v. injection. Each vial contains 50 mg of tenecteplase and excipients: L-arginine, 
phosphoric acid and polysorbate 80. 
Instructions for reconstitution of tenecteplase and use of the trial medications are given in the 
leaflet of the treatment kit. 
Enoxaparin (as enoxaparin sodium), Sanofi-Aventis, will be provided in multi-dose vials at a 
concentration of 100 mg/ml. Further excipients are: benzyl alcohol, sterile water for injection. 
Clopidogrel, Sanofi-Aventis, will be provided as tablets containing 75 mg of clopidogrel (as 
clopidogrel hydrogen sulphate) for oral use. The tablets further contain: mannitol, macrogol 
6000, microcrystalline cellulose, castor oil-hydrogenated, hydroxylpropylcellulose. The 
coating contains lactose, hypromellose, titanium dioxide, glycerol triacetate, iron oxide red 
and carnauba wax. 
There will be no comparator drug.  
There will be a parallel comparator treatment arm (Group B, for details refer to 4.1.2) using 
primary PCI (including any preceding and subsequent medication), which will be performed 
according to local standards and international guidelines. 
4.1.2 Methods of assigning patients to treatment groups 
Immediately after screening, eligible patients will be randomised to one of the following 
treatment groups to achieve equal numbers of patients in each group (approx. 1,000 patients 
per group): Pre-hospital fibrinolysis, antiplatelet and antithrombin treatment followed by 
catheterisation/PCI (Group A), or antiplatelet and antithrombin treatment and subsequent 
primary PCI according to local standards (Group B).  
Randomisation will be performed centrally by means of an interactive voice response system 
(IVRS) located at Leuven Coordinating Centre (LCC) in Leuven, Belgium, which has to be 
called by the investigator or an authorised member of site staff prior to randomising a patient. 
The randomisation procedure is described in detail in the Investigator Site File (ISF).  
4.1.3 Selection of doses in the trial 
Tenecteplase is given in a weight-adjusted dose regimen as described in the following section 
(4.1.4) according to the Basic Product Information (46).  
Based on the results of the ASSENT 3 and ExTRACT trials (please refer to section 1.2 for 
details) the LMWH enoxaparin will be used in the current trial using the recommended dose 
(30 mg i.v. bolus followed by 1 mg/kg every 12 hours) (26, 28). In the ExTRACT trial, the 
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dose of enoxaparin was reduced for patients of at least 75 years of age, which resulted in 
positive overall results for this age group (28). To conform to these results the initial intrave-
nous bolus of enoxaparin will be omitted and a reduced daily dose of enoxaparin (0.75 mg/kg 
instead of 1 mg/kg) will be administered in this trial for patients of at least 75 years of age. 
As described in section 1.2, the dose of clopidogrel chosen in this trial (300 mg p.o. loading 
dose followed by 75 mg p.o. q.d.) is based on the results of the CLARITY and COMMIT 
trials. Taking account of the increased bleeding risk in elderly patients (36) no loading dose 
of clopidogrel will be given for patients above 75 years.  
Acetylsalicylic acid is used as routine treatment after acute myocardial infarction and has 
been shown to be beneficial when combined with tenecteplase in several trials (25, 26). Usual 
recommendations are 150 – 325 mg p.o. given immediately, followed by 75 – 325 mg once 
daily with lifelong treatment unless it is contraindicated. 
As for the sequence of treatments, full dose tenecteplase administered as a single intravenous 
bolus over 5-10 seconds should be the first drug injected. The initial enoxaparin intravenous 
bolus of 30 mg is then to be administered via the same i.v. line after flushing. Then the two 
oral drugs, clopidogrel and acetylsalicylic acid should be given.  
Pre-hospital treatment will be followed by timely PCI, i.e. coronary angiography after 6 hours 
but within 24 hours and, if required, stenting/percutaneous transluminal coronary angioplasty 
(PTCA) or, in case of insufficient ST resolution at 90 min, rescue PCI. The time window of 
6-24 hours between pre-hospital fibrinolysis and catheterisation will allow for optimal 
balance between best care and resource use. The decision on rescue PCI will, however, be 
taken 90 min (or earlier if clinically indicated) after injection of tenecteplase according to the 
ST resolution (2, 17). 
In the primary PCI arm, treatment will be performed according to local standards. Preceding 
and concomitant medication – in particular antiplatelet and antithrombin drugs – will also be 
given according to local standards and international guidelines.  
Please also refer to section 1.2 for details. 
4.1.4 Selection and timing of doses for each patient 
Acetylsalicylic acid  
Acetylsalicylic acid is expected to be administered routinely to all patients (Group A and B) 
at a dose of 150 – 325 mg p.o. on scene (pre-hospital) and then 75 – 325 mg p.o. once daily 
for at least 90 days. Alternatively, if the patient is unable to ingest tablets, the initial dose may 
be given intravenously.  
If a patient has already taken acetylsalicylic acid within 12 hours prior to screening the 
patient will start with acetylsalicylic acid the next day.  
4.1.4.1 Group A 
Pre-hospital/ambulance treatment: 
Tenecteplase 
50 mg of drug reconstituted in 10 ml sterile water for injection will be given as single weight-
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adjusted i.v. bolus over 5 - 10 seconds 
Weight (kg) Dose (mg) Dose (ml)
≥55 to <60 30 mg   6 ml 
≥60 to <70 35 mg   7 ml 
≥70 to <80 40 mg   8 ml 
≥80 to <90 45 mg   9 ml 
≥90  50 mg 10 ml 
 
The total dose of tenecteplase is injected into an intravenous line of normal saline, as close to 
the insertion site as possible, using aseptic technique. The total dose is to be injected as a 
rapid intravenous bolus over 5 - 10 seconds. The intravenous line is to be flushed with normal 
saline immediately after injection of the tenecteplase bolus to ensure complete drug delivery. 
Tenecteplase must not be administered in dextrose or Ringer’s solution. 
The same i.v. line may be used for administration of the enoxaparin bolus after flushing the 
line with a sufficient amount of normal saline prior to the subsequent intravenous injection. 
 
Enoxaparin 
< 75 years:  
- 30 mg i.v. bolus  
- S.c. injections of 1.0 mg/kg every 12 hours until hospital discharge or for a maximum of 
4 days; the first injection should be given within 15 min of the bolus 
- For the first two subcutaneous injections, a maximum of 100 mg per injection should 
not be exceeded 
≥ 75 years:  
- No bolus; s.c. injections of 0.75 mg/kg every 12 hours until hospital discharge or for a 
maximum of 4 days; the first injection should be given immediately 
- For the first two subcutaneous injections, a maximum of 75 mg per injection should not 
be exceeded 
For patients of any age with a creatinine clearance < 30 ml/min, s.c. injections of 1.0 mg/kg 
will be given in intervals of 24 hours. 
 
Clopidogrel 
< 75 years:  
- 300 mg p.o. loading dose 
- 75 mg p.o. once daily as maintenance dose 
≥ 75 years:  
- No loading dose; 75 mg p.o. immediately after randomisation  
- 75 mg p.o. once daily (maintenance dose)  
 
Note: Additional treatment with acetylsalicylic acid is recommended as per local guidelines. 
The pre-hospital use of GP IIb/IIIa inhibitors is strongly discouraged (except for bail-out 
situations) 
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In-hospital treatment: 
All patients will be transferred to a hospital with PCI facilities or with routine early transfer 
and access to PCI facilities to ensure urgent rescue coronary intervention if required. 
The patient should be admitted to either the emergency department, coronary care unit or 
catheterisation laboratory (as per local practice). 
Assessment of reperfusion (by ECG) and evaluation of clinical symptoms will be done 
90 min after injection of tenecteplase. If clinically indicated and documented, this can be 
undertaken earlier. 
 
Enoxaparin 
If the last subcutaneous dose of enoxaparin was given more than 8 hrs before catheterisation, 
a dose of 0.3 mg/kg enoxaparin should be given intravenously. If the last subcutaneous dose 
of enoxaparin was administered within the previous 8 hrs, no additional enoxaparin should be 
given prior to catheterisation (please also refer to chapter 4.2.2 for restrictions).   
If a closure device is used, the sheath should be removed at the end of the PCI; however, if no 
closure device is used, the sheath should be removed at least 6 h after the last intravenous or 
subcutaneous dose of enoxaparin.   
After sheath removal further use of subcutaneous enoxaparin is at the discretion of the 
investigator (e.g. in patients where antithrombin treatment is indicated, as in atrial fibrillation 
etc.). 
Note: For patients who received enoxaparin in the pre-hospital setting a change to a different 
type of heparin (e.g., unfractionated heparin) prior to catheterisation should be avoided (cf. 
4.2.2). 
 
Clopidogrel 
Following usage of the study drug (until day 4 or hospital discharge, whichever occurs first) 
the maintenance dose of clopidogrel (75 mg p.o. per day) is recommended to be continued 
until day 30 for patients who did not receive a stent. If stenting was performed, clopidogrel 
should be given as routine treatment for a longer period according to accepted guidelines. 
 
Catheterisation: for details please refer to section 6.2.2.1. 
  
4.1.4.2 Group B 
Patients randomly assigned to treatment Group B will receive primary PCI according to local 
standards: 
 
Pre-hospital treatment: 
Concomitant antiplatelet and antithrombin treatment according to local standards which 
should be in accordance with international PCI guidelines (e.g., acetylsalicylic acid; 
clopidogrel 300 or 600 mg; unfractionated heparin/ enoxaparin/ bivalirudin) 
 
In-hospital treatment: 
At the receiving hospital transfer to the catheterisation laboratory should be organised as soon 
as possible as per local practice and in accordance with the protocol timelines. 
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The patient should be admitted to either the emergency department, coronary care unit or 
catheterisation laboratory (as per local practice).  
Concomitant treatment will be given as per local and international standards. 
Standard primary PCI 
Standard primary procedure following angiography (use of additional GP IIb/IIIa antagonists 
is at the investigator’s discretion). For details please refer to section 6.2.2.2. 
 
4.1.5 Blinding 
This is an open-label trial. Both treatment strategies will be performed in an unblinded 
manner.  
4.1.6 Packaging, labelling, and re-supply 
A treatment kit will be used in Group A only. It will contain tenecteplase, enoxaparin and 
clopidogrel (please refer to section 4.1.1 for identity of the investigational products. Kits will 
be labelled and packaged by Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, 
Germany, or a designated contractor. 
Contents of treatment box for Group A: 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
1 vial of 50 mg tenecteplase lyophilised powder for i.v. injection after reconstitution with 
sterile water for injection 
Pre-filled syringe of 10 ml sterile water for injection, for reconstitution of 50 mg 
tenecteplase, vial adapter and needle 
2 multi-dose vials (of 10 ml each) of 100 mg/ml enoxaparin, for i.v. and s.c. injections 
syringes and needles for i.v. injection and s.c. injection 
1 blister containing 28 film-coated tablets of clopidogrel with 7 tablets for use 
multilingual instructions for preparation, handling and administration of study medication 
loose stickers identifying patient, treatment and study (to be stuck on the Worksheet, or 
patient file, or any other patient-trial related documents to facilitate document handling by 
the research team) 
 
A sample drug label will be provided in the Investigator Site File (section 4). Labels will 
conform to the applicable regulatory requirements and indicate: 
Trial number 
Number of product and strengths or identification code 
Pharmaceutical dosage form 
Quantity of dosage units 
Route and mode of administration 
Term “for clinical trial use” (domestic language) 
Sponsor name and address (address of local Boehringer Ingelheim affiliate) 
Storage conditions 
Expiry date  
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Re-supply will be triggered by the number of kits used (i.e., patients randomised to group A) 
vs. the number of kits supplied to each site. The re-supply strategy will be described in detail 
in section 4 of the Investigator Site File. 
Please also refer to section 8.2.1 for drug accountability. 
4.1.7 Storage conditions 
The trial kit has to be stored at room temperature (< 25 °C) under normal hospital pharmacy 
conditions in a locked area with access limited to the investigator, study co-ordinator, 
pharmacist or other authorised study personnel.  
Kits must not be frozen. 
Lyophilized tenecteplase can be stored at up to 30 °C (86 °F); it should be protected from 
direct sunlight during extended periods. Since the reconstituted tenecteplase solution contains 
no preservatives, it is strongly recommended that it be used immediately after reconstitution, 
and under no circumstances should it be kept at 2 – 8 °C (36 – 46 °F) for longer than 8 hours 
before being used. 
Trial kits must not be handed out to patients. 
4.2 CONCOMITANT THERAPY 
4.2.1 Rescue medication and additional treatment(s) 
All concomitant or rescue treatment(s) taken during the course of the trial must be recorded 
in the source documents (e.g. patient files) and in the eCRF. 
Protamine (sulphate or hydrochloride) administered as a slow i.v. injection (1 mg protamine 
per 1 mg of enoxaparin) may be used to neutralise the effect of enoxaparin (maximum effect: 
60 % of the anti-Xa-activity).  
4.2.2 Restrictions 
Enoxaparin and heparin 
Patients who received enoxaparin in the pre-hospital setting should not be administered a 
different type of heparin prior to catheterisation (and vice versa). If heparin was used in the 
pre-hospital setting or early in-hospital period, subsequent treatment should not be switched 
to enoxaparin prior to catheterisation. 
Prior to catheterisation a dose of 0.3 mg/kg i.v. enoxaparin should be given to patients in 
Group A, unless the last subcutaneous dose of enoxaparin was given within the previous 8 hrs.  
GP IIb/IIIa antagonists 
GP IIb/IIIa antagonists should not be used in Group A except for bail-out situations in the 
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catheter laboratory. The use of GP IIb/IIIa antagonists in Group B is at the investigator’s 
discretion in accordance with STEMI/PCI guidelines and local standards. 
4.3 TREATMENT COMPLIANCE 
As all study treatments will be given out of hospital by the emergency physician and/or by 
experienced paramedics (as per local regulations) or in hospital by physicians and nursing 
staff, few compliance problems are foreseen. The only reasons for deviations from the 
treatment schedule in the protocol are considered to take place in emergency situations, for 
patients’ safety, or due to the rare events of dosing mistakes by the study team or due to 
damaged treatment kits. Used and unused treatment kits in Group A should be retained at the 
site by the study team and reconciled by the CRA with all available documentation on drug 
accountability (cf. also section 8.2.1).  
Information on dosing will be collected in the eCRF. 
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5. OBSERVATIONS 
All observations that represent or contribute to a trial endpoint are listed in the Trial Flow 
Chart on page 9. Observations will be taken during different trial periods: the pre-hospital 
(including ambulance) period, the in-hospital period, hospital discharge, end of trial (30 days) 
and the follow-up period (1-year), respectively, as described below. Data have to be recorded 
on appropriate written or electronic source data, e.g. ambulance file, patient file, hospital 
chart, electronic ECG recording or printout, laboratory print-out, or any trial-specific 
worksheet. All required data will be transcribed into the eCRF.  
If needed, worksheets and instruction leaflets will be made available to the ambulance or 
hospital staff in the local language to facilitate data collection and ensure sample collection 
required for diagnostic and baseline purposes.  
Please refer to section 8.2.4 for further details regarding source documents. 
5.1 EFFICACY  
The following observations will serve as efficacy endpoints and will be recorded if or when 
they occur during any of the trial periods until end of trial (day 30), except for ECG changes 
(until hospital discharge), rehospitalisation and mortality (1-year follow up). For a list of 
combined efficacy endpoints please refer to section 2.2.3. 
 
5.1.1 Efficacy endpoints within 30 days 
- All-cause mortality:   
In case of the patient’s death, the date and cause of death will be collected until day 30.  
- Cardiogenic shock:   
a) Systolic blood pressure < 90 mmHg for at least 30 min (or the need for supportive 
measures to maintain a systolic blood pressure of > 90 mm Hg) in the presence of a heart 
rate of > 60 beats/min in association with signs of end organ hypoperfusion (cool 
extremities, low urinary output < 30 ml/h and/or mental confusion)  
or 
b) Cardiac index < 2.2 l/min/m2 in the presence of a pulmonary capillary wedge pressure 
(PCWP) of > 15 mm Hg 
During the entire trial period (until day 30), the diagnosis of any post-discharge episode of 
cardiogenic shock will be made by collecting information on rehospitalisation according to 
hospital records and medical charts. 
- Congestive heart failure:   
At least one of the following conditions requiring treatment with diuretics has to apply: 
a) Pulmonary oedema/congestion on chest X-ray without suspicion of a non-cardiac cause 
b) Rales > 1/3 up from the lung base (Killip class 2 or higher)  
c) Pulmonary capillary wedge pressure (PCWP) >25 mmHg  
d) Dyspnoea with pO2 < 80 mmHg or O2 sat < 90 % (no supplemental O2) in the absence 
of known lung disease; 
Chest X-ray should be used throughout the study period to facilitate and confirm the 
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diagnosis of congestive heart failure. See section 10.3.3. 
Following hospital discharge any diagnosis of congestive heart failure will be made by 
collecting information on rehospitalisation until day 30 according to hospital records and 
medical charts. 
- Recurrent myocardial infarction:   
Recurrent myocardial infarction will be assessed by means of the ECGs (cf. section 5.1.2 
and section 6.2.2, Tables 4 and 5) and levels of cardiac enzymes/markers of necrosis 
indicative of re-infarction. (Definition of re-infarction is given in Appendix 10.3.4.) 
- Rehospitalisation for cardiac reasons:   
If, after discharge, a patient is readmitted to the hospital until day 30 due to cardiac 
reasons, this information must be recorded in a special hospitalisation section of the eCRF. 
Any event requiring unscheduled readmission will be considered a serious adverse event 
(SAE) and recorded as described in section 5.2.1. Only if readmission was scheduled, e.g. 
because of a routine or planned procedure, will the event leading to rehospitalisation not 
be considered as a serious adverse event. 
- Rehospitalisation for non-cardiac reasons:   
Data about any rehospitalisation for non-cardiac reasons occurring after discharge from 
initial hospitalisation until day 30 will be collected in a special hospitalisation section of 
the eCRF and have to be recorded on SAE reports in accordance with section 5.2.1. Only 
if rehospitalisation was scheduled, e.g. because of a routine or planned procedure, will it 
not be considered as a serious adverse event. 
 
5.1.2 Single efficacy endpoints at or before discharge 
- ECG changes (infarct size; aborted myocardial infarction):   
Twelve-lead ECGs for assessment of infarct size and aborted myocardial infarction will be 
obtained at screening/baseline for initial diagnosis in all patients and subsequently: 
Group A: 90 min after injection of tenecteplase or earlier if clinically indicated for assess-
ment of ST resolution (39). ECGs will be recorded immediately before the catheterisation 
and 30 minutes after the procedure (with or without PCI/stenting). In case of rescue PCI, 
ECGs will be taken immediately before the procedure and 30 minutes after the end of the 
procedure. 
Group B: an ECG will be taken prior to the PCI procedure and 30 minutes after the end of 
the procedure.  
For Groups A and B additional ECGs will be recorded before hospital discharge or on 4, 
whichever occurs first. Serial ECGs should be taken in case of symptoms of recurrent 
ischaemia or reinfarction. ECGs will be centrally adjudicated (cf. section 10.1.). 
ECG changes will be used to determine:  
- Infarct size: It will be calculated using Selvester QRS scoring system (40) previously 
used in the ASSENT 3/3 Plus and ASSENT 4 PCI studies (16, 26)  
- Aborted myocardial infarction (42): will be assessed by means of ECG as ST-segment 
resolution relative to baseline value and cardiac marker enzymes as done previously in 
the ASSENT 3/ 3 Plus studies (41). Peak levels of CK/CK-MB and/or troponin I/T will 
be collected at baseline, and 8-12 hrs and 24 hrs after randomisation. Quantification of 
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aborted myocardial infarction will be defined as CK/CK-MB levels ≤ 2 times the upper 
limit of normal (ULN) and/or troponin values analogous to this metric within 24 hours 
of randomisation.   
Only peak values of enzymes (expressed as times exceeding the upper limit of normal) 
will be recorded in the eCRF; the complete set of measured values will however be kept 
in the source documents.  
 
5.2 SAFETY 
5.2.1 General assessment of safety 
During screening and baseline the patient’s condition is assessed. Results of routine 
observations – demographic data, medical history and concomitant diseases, physical 
examination, vital signs, concomitant treatments – will be a part of the check for patient 
eligibility.  
- Medical history/current diseases:  
Data on previous and current relevant diseases will be collected, in particular information 
about any cardiovascular disease, prior cardiovascular event or surgery, hypertension, 
diabetes mellitus, renal insufficiency or lipo-metabolic disorder. 
- Concomitant therapy:  
Any chronic/concomitant antihypertensive, antiplatelet or anticoagulant treatment or 
otherwise significant therapy at screening and during the course of the study will be 
recorded. 
- Physical examination:  
It will be done as routine procedure at screening and will be used as check for patient 
eligibility. It comprises assessment of heart, lung, abdomen, etc. and should be recorded in 
the source documents. Results will not be collected in the eCRF. 
- Vital signs:  
Assessment of systolic and diastolic blood pressure and heart rate.  
- Pregnancy test:  
A urine pregnancy test is required in women of childbearing potential not using a 
medically accepted method of birth control. Data will only be recorded in source data.  
- Haematology:  
Haematology laboratory samples (at least haemoglobin, haematocrit, erythrocytes, leuco-
cytes and platelets) will be taken at baseline pre-hospital or, if this is not possible, on 
hospital arrival, and before hospital discharge according to the local hospital procedures. 
Values will be recorded in the eCRF as categories relative to the local reference ranges 
(i.e., below/within/above normal range). In case of bleeding or relevant laboratory abnor-
malities during the in-hospital period (until discharge) the laboratory values will be cross-
checked with baseline values and with adverse events reports. 
- Renal function:  
Serum creatinine level (as per Cockcroft-Gault formula) should be measured at the first 
occasion to rule out renal insufficiency. In Group A patients with a creatinine clearance of 
< 30 ml/min the dose of subsequent enoxaparin injections should be adjusted as described 
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in section 4.1.4.1) (30). 
- Blood glucose levels:   
The first in-hospital fasting value within 24 hours will be recorded in the eCRF as 
categories according to Pinto et al. (38). 
- Cardiac enzymes:  
Cardiac enzymes (CK, CK-MB) and/or troponin I/T will be measured at baseline, i.e. pre-
hospital or on arrival at hospital, as well as 8-12 hrs and 24 hrs after randomisation. If 
symptoms suggest occurrence of recurrent myocardial ischaemia or reinfarction during in-
hospital stay, enzyme levels should be determined to confirm the diagnosis. Individual 
values will not be recorded in the CRF, merely peak values expressed as times exceeding 
upper limit of normal (cf. also section 5.1.2). 
- 12-lead ECG:  
For ECG measurements please refer to section 5.1.2. 
- TIMI flow grade:  
TIMI flow grade of the infarct-related artery (IRA) will be assessed by standard angio-
graphic measurement during routine catheterisation in Group A or, for Group B, before 
PCI (first contrast injection) and after PCI (last contrast injection) as measured by the local 
investigator.  
- Killip class:  
Killip class will be determined before randomisation to check for patient eligibility and at 
hospital discharge. In case the ambulance staff consists of paramedics only, the 
responsible PI (or sub-investigator) must make sure the staff is sufficiently trained to 
perform the Killip classification. In the exceptional case that the Killip classification 
cannot be done at randomisation, it will be done upon arrival at the hospital. 
- Adverse events:   
Expected adverse events (AEs) related to tenecteplase are listed in the current version of 
the Tenecteplase Investigator Brochure (23 May 2006) (47), filed in the Investigator Site 
File, section 11.  
Adverse events will be recorded according to the following procedure (cf. Figure 1): 
All serious adverse events related to study treatment (Group A: tenecteplase, enoxaparin, 
clopidogrel, catheterisation/PCI; or Group B: catheterisation/PCI) will be reported on the 
SAE page as well as on the AE page of the eCRF.  
All serious adverse events neither related to any study treatment nor on the ‘list of STEMI-
related events’ (cf. events listed below) will be reported on the SAE page as well as on the 
AE page of the eCRF. 
All other serious adverse events not related to any study treatment, but on the ‘list of 
STEMI-related events’ (cf. events listed below) will only be recorded on the AE page of 
the eCRF. Only serious adverse events (SAEs) and serious/non-serious bleeds will be 
recorded in the eCRF. Non-serious adverse events other than bleeds will not be recorded 
in the eCRF. 
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Figure 1: Adverse event reporting  
 
YES 
NO 
Is the event serious?  
YES
NO
YES
NO
Is the event related to study treatment?   
(Group A: TNK, clopidogrel, enoxaparin, catheterisation/PCI; 
 Group B: catheterisation/PCI)   
Report on AE page in eCRF  
Report on SAE page in eCRF within 24 hrs 
Is the event on the list of STEMI-related events? 
Is it a non-serious bleed? 
Is it another non-serious event? 
Report on AE page in eCRF  
Report on SAE page in eCRF
within 24 hrs 
Report only on AE page in eCRF
Report only on AE page in eCRF
Do not record at all 
 
The following adverse events are expected as disease-related events (i.e. related to 
acute myocardial infarction): 
 
Arrhythmias 
All arrhythmias occurring later than 3 hours after fibrinolysis 
 
Ischaemia and symptoms of coronary artery disease 
Angina pectoris (stable) 
Angina pectoris (unstable) 
Back pain (of cardiac origin) 
Cardiac enzymes (abnormal) 
Cardiac markers (abnormal) 
Chest pain 
Electrocardiogram abnormalities 
Myocardial ischaemia 
Myocardial reinfarction 
Recurrent myocardial ischaemia 
ST-elevation 
Substernal chest pain 
Substernal pain 
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Artery disorders 
Aortic dissection 
Coronary artery dissection 
Coronary artery disorder 
Coronary artery thrombosis 
Coronary occlusion 
Vascular anomaly 
 
Cardiac failure 
Acute pulmonary oedema 
Cardiogenic shock 
Congestive heart failure 
Cor pulmonale 
Heart failure 
Left heart failure 
Pulmonary oedema 
Haemodynamic and circulatory shock 
 
Pericardium disorders 
Pericardial effusion 
Pericarditis 
 
Other cardiac disorders 
Acute mitral regurgitation 
Acute ventricular septum defect 
Cardiac rupture  
Cardiomyopathy 
Electro-mechanical dissociation 
 
Other events 
Deep thrombophlebitis 
Hypertension 
Livedo reticularis 
Peripheral oedema 
Peripheral vascular disorder 
Syncope 
Thrombocytosis 
Vascular disorder 
Venous thrombosis 
 
Detailed instructions – including a flow chart – on the reporting of adverse events will be 
provided in the Investigator Site File (ISF).  
During screening/baseline, the patient’s condition is assessed; any relevant changes from 
baseline will be noted subsequently in the source data (cf. section 8.2.4 for details).  
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Patients and investigators will be required – according to the procedure described above –
to report spontaneously any SAEs and bleeds as well as the time of onset, end and 
intensity of these events. A carefully written record of all SAEs and bleeds shall be kept 
by the investigator in charge of the trial. Records shall include data on the time of onset, 
end time and intensity of the event as well as any treatment or action required for the event 
and its outcome. All events, including those persisting after trial completion must be 
followed up until they have resolved or have been sufficiently characterised. 
Definitions and requirements for documentation and reporting of AEs and SAEs during a 
trial are provided in sections 8.4.1. 
Worsening of pre-existing conditions 
• Expected fluctuations or expected deterioration of the underlying disease will not be 
recorded as an AE. Worsening of the disease under study will be recorded as an AE if 
one of the following criteria is met. 
o Worsening of disease meets the criteria for an SAE. 
o Action is taken with investigational drug, i.e. dose is reduced or treatment 
discontinued or increased. 
o Treatment is required (concomitant medication is added or changed). 
o The investigator believes a patient has shown a clear, unexpected deterioration 
from baseline symptoms. 
• The same criteria as above apply to recording of AEs resulting from worsening of 
other pre-existing conditions. Pre-existing conditions are not recorded as AEs if they 
do not meet the criteria above. Specifically, the following will not be recorded as an 
AE: 
o Pre-existing conditions present at baseline, which remain unchanged during the 
trial. 
o Expected fluctuations or expected deterioration of a pre-existing condition. 
Vital Signs, ECG and Laboratory test results qualifying as AE 
Changes in safety tests including blood pressure, pulse rate, ECG and laboratory tests will 
be recorded as AEs, if: 
o they are not associated with an already reported AE, symptom or diagnosis  
 and  
o action is taken with the investigational drug, i.e. dose is reduced or treatment 
discontinued 
 or 
o treatment is required (concomitant medication is added or changed) 
 
5.2.2 Safety endpoints within 30 days 
Safety endpoints (for details on single vs. combined endpoints please refer to section 2.3) in 
this trial will be  
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- Clinically suspected stroke (total (fatal, disabling, non-disabling); ischaemic; intracranial 
haemorrhage)  
Patients experiencing any new neurological deficit at any time after randomisation (up to 
day 30) are to be taken for immediate (within 24 hours) computed tomography scanning 
(CT) or magnetic resonance imaging (MRI) to determine whether a stroke or intracranial 
haemorrhage (ICH) has occurred. CT is preferred, but MRI is also acceptable. In addition, 
all patients concerned should also be seen by a neurologist who may assist with the 
completion of the necessary documentation. For patients experiencing a non-fatal stroke 
during the initial in-hospital period, the modified Rankin scale (please refer to Appendix 
10.3.1) will be determined at hospital discharge.   
If, in case of a fatal stroke, no imaging was done, an autopsy should be performed 
whenever possible.   
Detailed information on the stroke (date and time of onset, type, symptoms, method of 
detection, outcome) will be collected in the eCRF.   
If a stroke occurs after discharge (up to day 30) or after referral to another hospital, the 
investigator and/or study team ought to use their best efforts to obtain the required 
information from that hospital.  
All strokes will be centrally adjudicated by the Stroke Review Panel (cf. section 8.10). 
- Non-intracranial bleeds (total, major, minor, and blood transfusions):   
Any reported bleeding, i.e. minor or major bleeds or any bleeding requiring blood 
transfusion, will be collected in the eCRF to assess the safety of the treatment. Serious 
bleeds will be reported as serious adverse events as described in section 5.2.1. All bleeds 
will be recorded on a special bleed page in the eCRF. For bleed categories please refer to 
Appendix 10.3.2. 
- Serious clinical events:  
Serious clinical events (including cardiac arrest/ventricular fibrillation/resuscitation and 
repeat target vessel recanalisation etc.) will be recorded on a special eCRF page. For all 
serious adverse events requiring expedited reporting according to the procedure described 
in section 5.2.1 a special eSAE report form in the eCRF must be completed in addition 
and must be submitted for further distribution to the Leuven Safety Group (LSG) within 
24 hours of the investigator becoming aware of the event (see section 8.4.1). 
 
5.3 OTHER 
5.3.1 Evaluations within 30 days 
- Duration of stay in CCU/ICU:  
Days from initial admission to the Coronary Care Unit (CCU) or Intensive Care Unit 
(ICU) until discharge to general ward, discharge from hospital or referral to another 
hospital or rehabilitation centre will be counted. 
- Duration of initial stay in hospital:   
Days from initial admission to hospital until discharge to home or referral to a rehabilita-
tion centre or nursing home will be calculated. Direct referral to another hospital (e.g. 
located closer to the patient’s home) will be considered as part of the initial stay. 
- Duration of rehospitalisation started until and including day 30 day:   
Boehringer Ingelheim (Schweiz) GmbH  Final, 25 September 2007 
BI Trial No.: 1123.28 Page 42 of 69 
The duration of any rehospitalisation subsequent to discharge from index hospitalisation 
that commenced within 30 days of randomisation (i.e., starting at the latest on day 30) will 
be counted. 
 
5.3.2 Evaluations within 1 year 
- All-cause mortality:    
The patient’s vital status at day 365 has to be evaluated. In case of the patient’s death 
between day 31 and day 365, the date and primary cause of death will be collected 
retrospectively at the 1 year follow up. 
- Rehospitalisation:  
If a patient is readmitted to the hospital for any reason between day 31 up to and including 
day 365, the date(s) and primary reason(s) must be recorded in the eCRF. 
 
5.3.3 Evaluations specific for Group A  
- Need of rescue PCI vs. revascularisation (as determined by investigator) and need of 
rescue PCI vs. revascularisation (centrally adjudicated):  
- A twelve-lead ECG for assessment of infarct size and aborted myocardial infarction 
will be obtained at screening/baseline for initial diagnosis. 
- At the receiving hospital an ECG will be recorded 90 min after injection of tenecte-
plase or earlier, if clinically indicated, for assessment of ST resolution.  
ECGs will be centrally adjudicated.  
ST resolution will be calculated according to methods described by Schroder (39) and will 
be used to determine the adherence to ECG criteria for rescue.  
Rescue coronary intervention is anticipated in approximately 25 % of patients receiving 
pharmacologic reperfusion therapy, if ST-segment resolution at 90 minutes or earlier, if 
clinically indicated, is < 50 % in the lead showing the greatest ST-segment elevation noted 
at baseline (randomisation) with the ECG measured from J-point with or without clinical 
symptoms.  
All rescue or urgent coronary interventions (as defined in section 6.2.2.1) will be centrally 
adjudicated to ensure protocol adherence with feedback provided to investigators as 
warranted.  
 
5.4 APPROPRIATENESS OF MEASUREMENTS 
All methods selected as efficacy and safety assessments in this trial are standard methods 
and/or widely used in trials on myocardial infarction.  
A strong step-wise correlation has been demonstrated across the lytic trials between the 
degree of ST-segment resolution and clinical outcome (39, 43). More recently analysis of 
resolution of maximal post-lysis ST-segment elevation from the single lead showing maximal 
initial ST-elevation has been shown to discriminate clinical outcomes following fibrinolysis 
for STEMI. Adoption of a 50 % cut-off for ST-segment resolution appears to confer similar 
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sensitivity for prediction of death or development of heart failure (around 90 %) to that of 
< 70 % maximal ST resolution threshold, with fewer false positive results (specificity around 
60 % at the 50 % threshold) (44). A single criterion of < 50 % ST-segment resolution in the 
lead with previous maximal ST-elevation acquired 90 minutes after fibrinolysis equips 
physicians and nursing staff with a simple, convenient and reasonably accurate bed-side tool 
to diagnose lytic failure. 
5.5 DATA QUALITY ASSURANCE 
This trial will be conducted according to the principles of the International Conference on 
Harmonisation (ICH), Declaration of Helsinki (1996), Good Clinical Practice (GCP), the 
applicable national and international laws and guidelines and Boehringer Ingelheim standard 
operating procedures (SOPs). The following measures will be taken to ensure accurate, 
consistent, complete and reliable data: 
- All required trial documents will be distributed to every trial site and kept in the Investi-
gator Site File (ISF). Local investigator meetings should be held before and during the 
course of the trial to assure a high quality and standardisation across sites (and countries).   
- Trial teams at the sites will be trained on protocol requirements, trial procedures, adverse 
event reporting, and remote data capture during the investigator meetings and/or by 
Clinical Research Associates (CRAs) during the respective monitoring visits. 
- ECGs for assessment of ST resolution, clinical and ECG data for assessment of aborted 
infarction, and clinical and imaging data for assessment strokes will be centrally 
adjudicated. 
- On-site monitoring: Data captured in the eCRF will be verified against source data and 
vice versa by CRAs. The identity and informed consent of all patients as well as SAE 
reporting will be checked. For the remaining parts of the eCRF 20 % source data 
verification will be performed as described in the Monitoring Manual.  
- The trial sites are to use validated and calibrated equipment (ECG) as required. 
- Auditing (internal and, if required by any regulatory authorities, external) will be 
performed as necessary. 
- Coding (e.g., according to MedDRA for adverse events) will be performed according to 
the company’s SOPs as described in the trial data management and analysis plan 
(TDMAP).  
- The data management procedures to ensure the quality of the data are described in detail in 
the (TDMAP) available in the CTMF. Data quality review meetings (DQRMs) will be 
held at regular intervals to check for data accuracy across sites and discrepancies will be 
handled as described in the TDMAP. 
 
Boehringer Ingelheim (Schweiz) GmbH  Final, 25 September 2007 
BI Trial No.: 1123.28 Page 44 of 69 
6. INVESTIGATIONAL PLAN 
Prerequisites: 
During the site selection process the qualification of a trial site for participation in the trial 
has to be determined. Sites must be experienced in pre-hospital fibrinolysis and have access 
to a catheterisation laboratory or cooperate with hospitals that provide or have access to a 
catheterisation laboratory to ensure the performance of delayed or rescue PCI, as required 
(Group A), or of primary PCI (Group B) according to the protocol. 
Before a trial site commences active participation in the trial, the composition of the 
ambulance staff involved in pre-hospital trial procedures should be clearly established. In 
instances where an ambulance vehicle is staffed entirely with paramedics, the principal 
investigator will confirm that the diagnosis of STEMI as well as the acquisition of consent 
and initiation of pre-hospital treatment is undertaken with appropriate ethical and regulatory 
authorisation as established in the region and/or country participating. In addition, the 
principal investigator must ensure that the staff is able to make any trial-related diagnoses as, 
e.g. congestive heart failure and cardiogenic shock and to perform the trial procedures 
according to protocol. Patient eligibility criteria will be provided in a translated comprehen-
sible version for use by paramedics and may also be re-phrased according to local guidelines. 
In addition, study medication logistics and associated procedures (including storage at 
hospital (pharmacy), interim storage in the ambulance, timely re-supply between hospital 
(pharmacy) and ambulance, transfer of used trial kits to hospital, etc.) must also be defined 
and documented before any site starts patient enrolment. 
6.1 VISIT SCHEDULE 
The trial consists of the following periods: 
- Pre-hospital period: screening/baseline assessments, informed consent, randomisation, 
pre-hospital treatment 
- In-hospital period: continuation of trial treatment as necessary 
- Discharge: pre-discharge assessments 
- End of trial (day 30): check for SAEs, rehospitalisation(s) and trial endpoints 
- 1-year follow-up: Check for vital status and rehospitalisation 
All assessments per visit are listed in the Trial Flow Chart on page 9 and are described in 
section 6.2 and, in more detail, chapter 5. 
6.2 TRIAL PROCEDURES AT EACH VISIT 
6.2.1 Pre-hospital period 
All patients will be screened, enrolled and receive treatment during the pre-hospital period. 
As soon as the ambulance arrives at the scene, the patient will be screened for eligibility by 
the investigator or authorised ambulance staff. Routine and/or rescue procedures are 
performed according to local practice and established guidelines. The following assessments 
will be done (for details of the individual assessments please refer to the Flow Chart on page 
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9 and to section 5.2):  
- Informed consent, demographic data, medical history/current diseases; physical examina-
tion, vital signs (blood pressure for evaluation of exclusion criterion 6), concomitant 
therapy; pregnancy test (if applicable), haematology, renal function, CK/CK-MB and/or 
troponin I/T (if pre-hospital blood samples are taken); twelve-lead ECG, Killip class; 
inclusion/exclusion criteria, randomisation, and administration of trial medication 
 
Randomisation and treatment allocation 
Patients will be randomised by authorised staff by means of an interactive voice response 
system (IVRS).  
Study treatment will be given according to the treatment group (A or B) randomly allocated 
by the IVRS.   
For patients assigned to Group A, any available kit may be taken, irrespective of the medica-
tion number. The medication number will also be the patient number.   
For patients allocated to Group B, no treatment kit will be used. The patient number will be 
assigned via the IVRS.   
The IVRS and randomisation procedure is described in detail in the Investigator Site File. 
 
For a detailed description of medical trial treatment please refer to section 4.1.4 of this 
protocol.  
Immediately following randomisation, subsequent in-hospital treatment of the patient 
according to protocol (i.e., availability of/or transfer for (diagnostic) catheterisation within 6 
to 24 hrs (Group A) or immediate primary PCI (Group B)) must be arranged with the 
receiving hospital.  
The following documents/samples should accompany the patient when transferred to the 
receiving hospital: 
- Diagnostic/baseline ECG, either as a paper copy or transferred electronically 
- Any ambulance files or worksheets in the ambulance where the required source data are 
recorded 
- Baseline blood samples for diagnostic cardiac enzymes (CK/CK-MB and/or troponin I/T), 
haematology, and renal function, if taken on scene/pre-hospital; In case no blood samples 
are taken on scene/pre-hospital, they should be taken immediately after arrival at the 
receiving hospital. 
 
6.2.2 In-hospital period (including discharge) 
The in-hospital period starts with the patient’s arrival at the hospital.  
Patients will be transferred to a hospital with PCI facilities or with routine early transfer to a 
PCI facility to ensure urgent rescue coronary intervention if required. 
A patient is considered admitted to hospital when he/she reaches the hospital alive and 
medical responsibility is taken over by the hospital medical team (irrespective of whether it 
occurs in the emergency room, the coronary care unit (CCU), the intensive care unit (ICU) or 
any other ward/unit).  
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- If not already taken pre-hospital, baseline blood samples for diagnostic cardiac enzymes 
(CK/CK-MB and/or troponin I/T), renal function, and haematology should be taken as 
soon as possible after hospital arrival.  
- Patients will then receive further treatment according to the treatment group they have 
been randomised to.  
 
6.2.2.1 Group A 
Assessment of reperfusion 
At the receiving hospital patients should be admitted to either the emergency department, 
coronary care unit or catheterisation laboratory (as per local practice) to assess reperfusion.  
The patient's need for rescue coronary intervention will be assessed by both ECG and 
evaluation of clinical symptoms 90 min after injection of tenecteplase or earlier, if clinically 
indicated. These patients may undergo coronary intervention immediately, if indicated, in 
accordance with the protocol criteria described below.   
An additional ECG should be taken before starting the procedure, if there are clinical or 
electrocardiographic signs of reperfusion that have occurred after the previous ECG. In this 
case the planned coronary intervention may be postponed. 
 
Catheterisation 
- If ST-segment resolution is ≥ 50 % in the qualifying lead (that had the maximum initial 
ST-segment elevation in the baseline ECG), diagnostic coronary angiography (followed 
by elective PCI +/- stenting, if indicated) should be performed no sooner than 6 hours, but 
within 24 hours after administration of tenecteplase. This will be considered as planned 
catheterisation according to protocol 
- If ST-segment resolution is < 50 % relative to the ST-segment elevation in the qualifying 
lead at baseline, irrespective of the presence or absence of clinical symptoms, rescue 
coronary intervention should be performed promptly.  
- If any of the following indications require coronary intervention (irrespective of previous 
ST-segment resolution), urgent coronary intervention is indicated at any time: 
• haemodynamic instability (presence of any of the following requiring inotropic 
support: sustained hypotension, cardiogenic shock, or congestive heart failure) 
• refractory ventricular arrhythmias requiring cardioversion or pharmacological 
treatment 
• worsening ischaemia  
• progressive or sustained ST-segment elevation which, in the judgement of the 
investigator, requires immediate coronary intervention 
 
All rescue and urgent coronary interventions will be adjudicated by an independent clinical 
expert panel. 
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Further ECG measurements 
Further ECG measurements are listed in Table 4. 
 
Table 4: Overview of ECG measurements in Group A 
Timing of ECG Location  Reason for ECG 
Baseline  Pre-hospital: 
on site/ambulance 
ECG for assessment of STEMI 
entry criteria 
90 min after injection of 
tenecteplase (or earlier, if 
clinically indicated) 
In-hospital: 
emergency dept. or CCU 
Assessment of reperfusion 
In case of catheterisation (with or 
without PCI/stenting) or rescue or 
urgent PCI, respectively:  
- immediately before  
- and 30 min after the end of 
 the procedure.   
In-hospital: catheter 
laboratory 
 
Reassessment of reperfusion 
Any time, if indicated 
(serial ECGs) 
In-hospital Verification of ischaemia or 
reinfarction  
Prior to hospital discharge or on 
day 4 (earliest option) 
In-hospital Control 
 
Collection of data 
During the patient’s stay in hospital (i.e., until and including the day of discharge) the follow-
ing data will be collected:  
- Concomitant therapy 
- First glucose (fasting) value available within 24 hours of randomisation 
- CK/CK-MB and/or troponin I/T 8-12 hrs and 24 hrs after randomisation, respectively, and 
also at any time in case of signs and symptoms suggestive of recurrent myocardial 
ischaemia or reinfarction 
- 12-lead ECG (please refer to Table 4) 
- Data on catheterisation/coronary intervention(s) 
- TIMI flow grade (during catheterisation) 
- Any occurrence of a trial endpoint 
- Any occurrence of adverse events, and serious adverse events/serious clinical events 
For details regarding trial endpoints and adverse events please refer to sections 5.1 and 5.2. 
The following assessments will be performed on the day of discharge from hospital (or 
transfer to a rehabilitation centre or nursing home) or on day 4, whichever occurs first: 
- Blood test for haematology as per hospital routine 
- Killip class  
- 12-lead ECG (cf. Table 4) 
- Any occurrence of a trial endpoint 
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- Any occurrence of adverse events, and serious adverse events/serious clinical events 
6.2.2.2 Group B 
Patients in Group B will receive medical treatment before, during and after primary PCI 
according to established local standards. Additional GP IIb/IIIa antagonists may be given at 
the investigator’s discretion. 
During the in-hospital period several 12-lead ECGs will be taken as summarised in Table 5. 
 
Table 5: Overview of ECG measurements in Group B  
Timing of ECG Location  Reason for ECG 
Baseline  Pre-hospital: 
on site/ambulance 
ECG for assessment of STEMI 
entry criteria 
Immediately prior to PCI In-hospital: catheter laboratory Assessment of reperfusion 
30 min after the end of the 
intervention  
In-hospital Reassessment of reperfusion 
Any time, if indicated 
(serial ECGs) 
In-hospital Verification of ischaemia or 
reinfarction  
Prior to hospital discharge 
or on day 4 (earliest option) 
In-hospital Control 
 
During the patient’s stay in hospital, data on primary PCI will be collected. All further assess-
ments during the initial hospitalisation and prior to the patient’s discharge from hospital (or 
transferral to a rehabilitation centre or nursing home) are identical to those assessed in Group 
A (please refer to the above paragraph, 6.2.2.1). 
6.2.3 End of trial and follow-up period 
The trial will end after the last patient has completed the end-of-trial visit (last patient out). 
However, if possible, follow-up information will be collected for all patients that are alive at 
the end-of-trial visit. 
6.2.3.1 End of trial (day 30) 
The end-of-trial visit will take place at day 30. (Data may however be collected until and 
including day 37.)   
The following data will be collected: 
- Modified Rankin Scale (only in case of suspected stroke) 
- Data on any rehospitalisation occurring after hospital discharge up to (including) day 30 
- Any occurrence of a trial endpoint since hospital discharge or (if the patient is still hospi-
talised) of any trial endpoint that has not yet been recorded, including ECG and test results 
for cardiac enzymes in case of symptoms suggestive of recurrent ischaemia or myocardial 
infarction 
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- Any occurrence of adverse events, and serious adverse events/serious clinical events since 
hospital discharge or (if the patient is still hospitalised) that have not yet been recorded 
6.2.3.2 Follow-up 
Data for the 1-year follow up should be collected at day 365 (up to and including day 395). 
The required evaluations may be assessed via phone, if a physical visit is not performed. 
1-Year follow-up: 
- Vital status/all cause mortality (since day 30) 
- Any rehospitalisation since end of trial (including cause of rehospitalisation) 
 
6.3 REMOVAL OF PATIENTS FROM THERAPY ASSESSMENT 
As soon as the patient is randomised, the patient is considered a trial participant irrespective 
of whether he or she received any trial-specific treatment or not. 
A patient may withdraw from the trial at any time without the need to justify the decision. 
In case of withdrawal all data collected until (and including) the day of withdrawal will be 
kept in the trial database.  
The investigator will nevertheless be asked to provide at least the patient’s survival status at 
the end-of-trial visit. 
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7. STATISTICAL METHODS AND DETERMINATION OF 
SAMPLE SIZE 
7.1 STATISTICAL DESIGN / MODEL 
The trial is a prospective, multi-centre, international, randomised (1:1), open-label, parallel-
group comparison, conducted for investigating the efficacy and safety of 
A. Tenecteplase + enoxaparin + clopidogrel (experimental, Group A) 
B. Primary PCI according to local standards (reference, Group B) 
in patients with acute myocardial infarction randomised < 3 hours from symptom onset. 
The principal aim of the trial is to evaluate the safety and efficacy in the treatment groups 
measured by single and composite endpoints as listed in section 2.1. 
7.2 NULL AND ALTERNATIVE HYPOTHESES 
No confirmatory statistical hypothesis test is pre-specified. All statistical tests are of 
exploratory nature for formal statistical hypotheses generation. All statistical analyses will be 
done by presenting confidence intervals and descriptive p-values. 
7.3 PLANNED ANALYSES  
Baseline characteristics will be tabulated and differences between the two treatment groups 
will be examined by means of descriptive statistics. 
The primary analysis is an intent-to-treat analysis of all randomised patients. Patients will be 
analysed according to the treatment group to which they were randomised, irrespective of 
which study drug was given or if any study drug was received. 
For all single and composite endpoints the 95 % confidence intervals (two-sided) will be 
presented separately for each treatment group. 
Between-treatment-group comparisons will be done by presenting the 95 % confidence 
intervals (two-sided) of the corresponding difference and/or odds-ratio for each clinical 
endpoint. 
Statistical methods will include chi-square tests, Fisher Exact tests and logistic regression. 
For sensitivity analyses variables to be included in the models will be treatment type, age, 
gender, diabetes mellitus and /or blood glucose, hypertension, angina pectoris, Killip class, 
previous infarction, previous stroke, pulse, and infarct location. 
7.3.1  Subgroup analysis 
The usual subgroups as predefined in the ASSENT II / III publications will be analysed 
descriptively (25, 26). 
 
7.3.2 Safety analyses 
Safety parameters will be analysed as described above. 
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7.3.3 Interim analyses 
No formal interim analysis is foreseen. Continuous safety monitoring will be done by a Data 
and Safety Monitoring Board (DSMB) with particular emphasis on the incidence of systemic 
bleeding and intracranial haemorrhage (ICH); details are documented in the DSMB charter.  
7.4 HANDLING OF MISSING DATA 
No imputation of missing data is foreseen. Best efforts will be made to collect complete data 
for the clinical endpoints of interest. Distribution of the missing data will be checked across 
groups. 
7.5 RANDOMISATION 
The randomisation schedule will be set up by the Clinical Trial Supplies Centre of 
Boehringer Ingelheim.  
The randomisation will be stratified by centre and, within the centres, performed in blocks to 
ensure balanced distribution of the treatment groups at any time. Randomisation will be 
available daily for 24 hours via a centralised telephone Interactive Voice Response System 
(IVRS). Each site using IVRS will be provided with a telephone number and a PIN code that 
will connect them to a computerised script identifying the treatment group. For details on the 
use of IVRS see the manual in the Investigator Site File, Section 4. 
Patients are considered randomised as soon as the treatment group has been assigned.   
The block size will be documented in the Clinical Trial Report.  
7.6 DETERMINATION OF SAMPLE SIZE 
As all statistical tests are of exploratory nature for formal statistical hypotheses generation, 
the sample size estimation of 1,000 patients per group is derived from the accuracy of the 
estimation of the 95 % confidence intervals (two-sided) for each endpoint within the two 
treatment groups as well as of the 95 % confidence intervals (two-sided) for between-group 
comparisons. 
Table 6 illustrates a scenario for the single and composite endpoints presenting the width of 
the corresponding 95 % confidence intervals (two-sided), given a number of about 1,000 
patients per treatment group. 
Table 6: Width of the 95 % Confidence Interval (CI) for various endpoints 
Safety and Efficacy Endpoints Expected incidence 
 
Approx. width of 
95 % CI (two-sided) 
Single efficacy and safety 
endpoints at day 30 
  
All-cause mortality 4.0 % ±1.2 % 
Cardiogenic shock 3.0 % ±1.1 % 
Congestive heart failure 6.0 % ±1.5 % 
Recurrent myocardial infarction 3.0 % ±1.1 % 
Intracranial haemorrhage 0.9% ±0.6 % 
Total stroke 1.5 % ±0.8 % 
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Main efficacy composites at day 
30 
Expected incidence 
 
Approx. width of 
95 % CI (two-sided) 
Death and shock 5.5 % ±1.4 % 
Death and shock and CHF 11.0 % ±1.9 % 
Death and shock and reinfarction 13.0 % ±2.1 % 
Death and shock and CHF and 
reinfarction 
15.0 % ±2.2 % 
 
Furthermore, in case of a sample size of 1,000 patients per treatment group, Table 7 below 
shows how much the point estimate in the experimental groups would have to be better than 
in the reference group to exclude with 80 % power a worsening (minimal important differ-
ence, MID) of 1-2 %, by means of 95 % confidence intervals (two-sided) for differences. 
Table 7: The necessary advantage of the point estimate in the experimental arm to exclude 
the MID shown when both reference and experimental group have 1,000 patients each 
Event rate of endpoint MID*) = 1 % MID = 1.5 % MID = 2 % 
3 % 1.0 % 0.6 % 0.1 % 
4 % 1.3 % 0.9 % 0.4 % 
5.5 % 1.7 % 1.2 % 0.8 % 
6 % 1.8 % 1.3 % 0.9 % 
7 % 2.0 % 1.5 % 1.1 % 
9 % 2.4 % 1.9 % 1.5 % 
11 % 2.7 % 2.2 % 1.8 % 
13 % 3.0 % 2.5 % 2.1 % 
15 % 3.3 % 2.8 % 2.4 % 
*) MID: minimal important difference 
The figure below (Figure 2) graphically illustrates the above-mentioned scenarios. 
Figure 2: A 4 % event rate in reference group and an MID of 1 % (power 80 %) 
 
ASSENT-III Issues 1
2%0%- 2% 4%
• To exclude (95% CI, two-sided) the possibility of 1% worsening for a 
difference in proportions, the point estimate in the experimental group 
would have to be at least 1.3% better than in the reference group
• For  group comparison (1,000  vs. 1,000 pts)
Experimental better Experimental worse
MID
-1.3-3.6 1.0
1,000 vs.1,000
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8. ADMINISTRATIVE MATTERS 
The trial will be carried out in compliance with the protocol, the principles laid down in the 
Declaration of Helsinki, version as of October 1996, in accordance with the ICH Harmonised 
Tripartite Guideline for Good Clinical Practice (GCP) and relevant BI SOPs. 
The applicable international and local laws and treatment guidelines will be adhered to. 
Insurance Cover: The sponsor will take out no-fault insurance cover for all patients included 
in the trial. The terms and conditions of this insurance cover are available to the investigator 
and the patients in the ISF (Investigator Site File). 
8.1 ETHICS 
8.1.1 Institutional Review Board or Independent Ethics Committee 
The trial will not be initiated before the protocol (CTP) and informed consent and patient 
information form have been reviewed and received approval / favourable opinion from the 
local Institutional Review Board (IRB) / Independent Ethics Committee (IEC) and approval 
by the Competent Authority (CA) or applicable regulatory authority as required by local laws 
and regulations. Should a CTP amendment be made that needs IRB / IEC approval and 
authority notification/approval, the changes in the CTP will not be instituted until the 
amendment and revised informed consent (if appropriate) have been reviewed and received 
approval / favourable opinion from the local IRB / IEC and the CA or applicable regulatory 
authority, as required by local laws and regulations. A CTP amendment intended to eliminate 
an apparent immediate hazard to patients may be implemented immediately providing that 
the regulatory authority and IRB / IEC are notified as soon as possible and an approval is 
requested. CTP amendments exclusively for logistical or administrative changes may be 
implemented with notification of the IRB / IEC and CA or competent authority only. 
The constitution of the IRB / IEC must meet the requirements of the participating country / 
countries. A list of the IRB / IEC members, with names and qualifications, needs to be 
provided by the IRB / IEC to the investigator or, if applicable, sponsor. The investigator or, if 
applicable, sponsor must provide to the regulatory authorities the name and address of the 
IRB / IEC along with a statement from the IRB / IEC that it is organised according to GCP 
and the applicable laws and regulations. The IRB / IEC must perform all duties outlined by 
the requirements of the participating country / countries.  
8.1.2 Informed Consent and Patient Information 
Prior to patient participation in the trial, written informed consent must be obtained from each 
patient (or the patient’s legally accepted representative) according to the regulatory and legal 
requirements of the participating country. Each signature must be dated by each signatory and 
the informed consent and any additional patient information form retained by the investigator 
as part of the trial records. A signed copy of the informed consent and any additional patient 
information must be given to each patient or the patient’s legally accepted representative.  
The patient must be informed that his/her personal trial-related data will be used by Boeh-
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ringer Ingelheim in accordance with the local data protection law. The level of disclosure 
must also be explained to the patient. 
The patient must be informed that his / her medical records may be examined by authorised 
monitors (CML/CRA) or Clinical Quality Assurance auditors appointed by Boehringer 
Ingelheim, by appropriate IRB / IEC members, and by inspectors from regulatory authorities.   
Should a CTP amendment become necessary, the patient consent form and patient informa-
tion form may need to be revised to reflect the changes to the CTP. It is the responsibility of 
the investigator or, if applicable, sponsor to ensure that an amended consent form is reviewed 
and has received approval / favourable opinion from the IRB / IEC and CA or applicable 
regulatory authority, as required by local laws and regulations, and that it is signed by all 
patients subsequently entered in the trial and those currently in the trial, if affected by the 
amendment. 
8.2 RECORDS 
8.2.1 Drug accountability 
Drug supplies, which will be provided by the sponsor or a CRO appointed by the sponsor, 
must be kept in a secure, limited access storage area under the storage conditions defined by 
the sponsor. Where necessary, a temperature log must be maintained to make certain that the 
drug supplies are stored at the correct temperature. 
The investigator or pharmacist or investigational drug storage manager must maintain records 
of the product’s delivery to the trial site, the inventory at the site, the use by each patient, and 
the return to the sponsor or alternative disposition of unused product(s). These records will 
include dates, quantities, batch/serial numbers, expiry dates, and the unique code numbers 
assigned to the investigational product(s) and trial patients. The investigator / pharmacist / 
investigational drug storage manager will maintain records that document adequately that the 
patients were provided the doses specified by the CTP and reconcile all investigational 
product(s) received from the sponsor. At the time of return to the sponsor or appointed CRO, 
the investigator / pharmacist / investigational drug storage manager must verify that all 
unused or partially used drug supplies have been returned by the clinical trial patient and that 
no remaining supplies are in the investigator’s possession. 
8.2.2 Emergency code break 
No emergency code break is necessary because this trial is an open-label study. 
8.2.3 Case Report Forms (CRFs) 
All of the clinical data will be captured via electronic data capture (EDC) using the Hypernet 
system, a web-based tool, provided by Hyperphar S.p.A, Milan, Italy. The investigator site 
staff will enter and edit the data via a secure network, with secure access features (username, 
password and secure identification – an electronic password system). A complete electronic 
audit trail will be maintained. The investigator will approve the data using an electronic 
signature (Ref: 21 CFR Part 11), and this approval is used to confirm the accuracy of the data 
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recorded. 
Electronic CRFs (eCRFs) will be used for all patients. The investigator’s data will be 
accessible from the investigator’s site throughout the trial. Relevant medical history prior to 
enrolment will be documented at the baseline visit. Thereafter during the trial, narrative 
statements relative to the patient’s progress during the trial will be maintained. The electronic 
CRFs must be kept current to reflect patient status at each phase during the course of the trial. 
The patients must not be identified on the electronic CRF by name. Appropriate coded 
identification (i.e. Patient Number) must be used. The investigator must make a separate 
confidential record of these details (patient identification code list) to permit identification of 
all patients enrolled in a clinical trial in case follow-up is required. While a trial is ongoing 
and until the access to the database has been terminated, there will be no Documentation of 
Changes (DOCs). All changes will be requested from the investigator through the EDC 
system. If a change is necessary once the investigator has no further access to the database, a 
DOC will be sent to the investigator for confirmation of the change. The investigator’s 
signature is requested to show he/she agrees with the change that was made. The original 
DOC is kept by the investigator. 
Copies of the electronic CRF together with all data changes made will be supplied to the 
investigator at the end of the trial. The investigator will be responsible for retaining all 
records pertaining to the trial as specified in the appropriate contract. 
8.2.4 Source documents 
Source documents provide evidence for the existence of the patient and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s site. 
Data entered in the eCRFs that are transcribed from source documents must be consistent 
with the source documents or the discrepancies must be explained. The investigator may need 
to request previous medical records or transfer records, depending on the trial; also current 
medical records must be available. 
The following data to be reported in the eCRF need to be derived from the source documents: 
• Patient identification (gender, date of birth) 
• Patient participation in the trial (substance, trial number, patient number) 
• Dates of patient’s visits 
• Medical history (including trial indication and concomitant diseases, if applicable) 
• Medication history 
• Adverse events (onset date) 
• Serious adverse events (onset date) 
• Concomitant therapy (onset date, changes) 
• Originals or copies of laboratory results and trial-related assessments (in validated 
electronic format, if available) 
• Conclusion of patient’s participation in the trial 
8.2.5 Direct access to source data / documents 
The investigator / institution will permit trial-related monitoring, audits, IRB / IEC review 
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and regulatory inspection, providing direct access to all related source data / documents. 
Electronic CRFs and all source documents, including progress notes and copies of laboratory 
and medical test results, must be available at all times for review by the sponsor’s clinical 
trial monitor and inspection by health authorities (e.g. FDA). The Clinical Research Asso-
ciate (CRA) / on-site monitor may review all eCRFs, and written informed consents. The 
accuracy of the data will be verified by reviewing the documents described in section 8.2.4. 
8.3 QUALITY ASSURANCE AUDIT 
A quality assurance audit of this trial may be conducted by the sponsor or sponsor’s 
designees. The quality assurance auditor will have access to all medical records, the 
investigator’s trial-related files and correspondence, and the informed consent documentation 
that is relevant to this clinical trial. 
8.4 PROCEDURES 
8.4.1 Adverse events 
An adverse event (AE) is defined as any untoward medical occurrence, including an exacer-
bation of a pre-existing condition, in a patient in a clinical investigation who received a 
pharmaceutical product. The event does not necessarily have to have a causal relationship 
with this treatment. 
All adverse events occurring during the course of the clinical trial (i.e., from signing the 
informed consent onwards through the observational phase) will be collected, documented 
and reported to the sponsor by the investigator according to the specific definitions and 
instructions detailed in the ‘Adverse Event Reporting’ section of the Investigator Site File 
and in section 5.2.1 of the trial protocol. 
A serious adverse event (SAE) is defined as any AE which results in death, is immediately 
life-threatening, results in persistent or significant disability / incapacity, requires or prolongs 
patient hospitalisation, is a congenital anomaly / birth defect, or is to be deemed serious for 
any other reason representing a significant hazard, which is comparable to the afore-
mentioned criteria. 
All serious adverse events and non-serious bleeds will be fully documented in the appropriate 
eCRFs. For each adverse event, the investigator will provide the onset, end, intensity, treat-
ment required, outcome, seriousness and action taken with the investigational drug. The 
investigator will determine the relationship of the investigational drug to all AE as defined in 
the 'Adverse Event Reporting' section of the Investigator Site File.  
The basis for judging the intensity of the AE as well as the causal relationship between the 
investigational product and the AE is described below. 
Intensity of event 
• Mild:  Awareness of sign(s) or symptom(s) which is/are easily tolerated 
• Moderate: Enough discomfort to cause interference with usual activity 
• Severe: Incapacitating or causing inability to work or to perform usual 
activities 
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Causal relationship 
Medical judgement should be used to determine the relationship, considering all relevant 
factors, including pattern of reaction, temporal relationship, de-challenge or re-challenge, 
confounding factors such as concomitant medication, concomitant diseases and relevant 
history. Assessment of causal relationship should be recorded in the eCRF. 
• Yes: There is a reasonable causal relationship between the investigational drug 
administered and the AE.  
• No: There is no reasonable causal relationship between the investigational drug 
administered and the AE.  
The causal relationship must be provided by the investigator for all potential trial drugs, i.e. 
the BI trial drug and for all other trial drugs (i.e. any active comparator or placebo according 
to the trial design). 
The investigator has the obligation to report AEs during the specified observational phase. If 
defined in the CTP, the investigator also has the responsibility to report AEs occurring in a 
certain period after a patient completes the trial. Any AEs reported to the sponsor during this 
phase must be documented in the safety database. 
SAEs are to be reported to Leuven Safety Group (LSG) using the eCRF version of the BI 
Serious Adverse Event Report Form in Hypernet including a documented causal relationship 
assessment and providing as much detail regarding the SAE as possible. With receipt of 
follow-up information, all remaining fields on the eSAE form are to be completed or updated. 
All SAEs and non-serious bleeds must be entered by the investigator on the AE page of the 
eCRF.  
The following events will trigger the completion of an eSAE form for expedited reporting: 
• Serious and treatment-related SAEs 
• Serious, not treatment-related and not mentioned on the ‘list of STEMI-related events’ 
All events requiring expedited reporting must be reported in the eCRF within 24 hours 
(1 workday) after the Investigator (or any member of the study team) has become aware of 
the event. Timelines are the same for initial reports and for follow-up reports. 
The eSAEs reports will trigger an automatic alert to the LSG (via e-mail) for further 
processing. 
Any serious AE or any bleed, whether or not considered related to the investigational 
product, and whether or not the investigational product has been administered, must be 
reported immediately in the eCRF, if it meets the criteria for expedited reporting described 
above and in section 5.2.1. Expedited reporting of serious adverse events, e.g. suspected 
unexpected serious adverse reactions (SUSARs), will be done according to local regulatory 
requirements. Further details regarding this reporting procedure are provided in the ISF. 
Following every eSAE report, the Leuven Safety Group (LSG), who acts as the central safety 
processing group for the whole study, will assess the drug relationship, the category classifi-
cation, listedness and seriousness of reported SAE cases and will enter all required SAE 
reports into a database provided by the sponsor. LSG must provide a written report of the 
serious AE and any sequelae to Corporate Drug Safety according to the appropriate 
Corporate SOP(s). These narratives, which confirm the information collected from the 
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investigator, may give additional information not available at the time of the initial report. 
The LSG will transmit all reports requiring expedited reporting in a defined electronic format 
within the required timelines to Corporate Drug Safety. Furthermore, the LSG will provide 
the DSMB with safety/efficacy data as requested. Details are described in the Working 
Instructions for the Leuven Safety Group: Processing and reporting of serious adverse events 
in the STREAM trial.  
8.4.2 Emergency procedures 
Not applicable.  
8.5 RULES FOR AMENDING PROTOCOL 
All CTP amendments must be documented, dated and signed by all signatories (or their 
successors) of the original protocol. This also applies to any local amendment that may 
become necessary. Amendments need to be submitted to the IRB / IEC for review/approval 
and to the competent authority (CA) or the applicable regulatory authority for approval/ 
notification, as described in section 8.1.1. 
8.6 DISCONTINUATION OF THE TRIAL BY THE SPONSOR 
Boehringer Ingelheim reserves the right to discontinue the trial at any time for the following 
reasons (please also refer to section 8.10): 
1.) Failure to meet expected enrolment goals, 
2.) emergence of any efficacy/safety information that could significantly affect continuation 
of the trial or any other administrative reasons, 
3.) violation of GCP, the CTP, or the contract by a trial site or investigator, disturbing the 
appropriate conduct of the trial. 
The investigator / the trial site will be reimbursed for reasonable expenses incurred in case of 
trial termination (except in case of the third reason). 
8.7 STATEMENT OF CONFIDENTIALITY 
Individual patient medical information obtained as a result of this trial is considered 
confidential and disclosure to third parties is prohibited with the exceptions noted below.  
Patient confidentiality will be ensured by using patient identification code numbers. 
Treatment data may be given to the patient’s personal physician or to other appropriate 
medical personnel responsible for the patient’s welfare. Data generated as a result of the trial 
need to be available for inspection on request by the participating physicians, the sponsor’s 
representatives, by the IRB / IEC and the regulatory authorities. 
8.8 PUBLICATION POLICY 
Boehringer Ingelheim is as much as possible dedicated to support process of free exchange of 
relevant scientific information.   
Any publication of the result of this trial must be consistent with the Boehringer Ingelheim 
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publication policy. The rights of the investigator and of the sponsor with regard to publication 
of the results of this trial are also described in the investigator contract.  
A report, comprising both the clinical and statistical aspects, will be prepared by the sponsor. 
This report will be reviewed and signed by the Study Chairman. It will be regarded as 
confidential and may be submitted to regulatory authorities worldwide. 
This study represents a joint effort between the sponsor and the investigators, and as such, the 
parties agree that the recommendation of any party concerning manuscripts or text shall be 
taken into consideration in the preparation of final scientific documents for publication or 
presentation. 
The Executive Committee in conjunction with the Steering Committee will prepare a 
manuscript(s) plan to ensure timely and high quality presentation and publication of the study 
results and provide this to the sponsor for due consideration.  
The Study Chairman will submit any manuscript to the sponsor for comment and release 
prior to the actual submission to a learned society or scientific journal to ensure the validity 
of the data prior to publication. One week should be allowed for the sponsor’s review of 
papers (abstracts) planned to be submitted to a learned society and four weeks should be 
allowed for the sponsor to review papers planned to be submitted to a scientific journal. 
Investigators are encouraged to propose additional analyses from the final available data. All 
proposed publications and presentations by investigators or their personnel and associates 
resulting from or relating to this study must be submitted to the Executive Committee in 
conjunction with the Steering Committee for review and approval prior to submission for 
publication or presentation. Manuscripts submitted for publication must be in compliance 
with applicable laws and regulations regarding patient privacy.  
If any such proposed publication or presentation contains patentable subject matter which, at 
the sponsors' sole discretion warrants intellectual proprietary protection, the sponsor may 
delay publication or presentation for up to six weeks after the investigator’s approval for the 
purpose of pursuing such protection. 
8.9 COMPLETION OF TRIAL 
For EU member states: 
The IEC/competent authority in each participating EU member state needs to be notified 
about the end of the trial (last patient out) or early termination of the trial.  
8.10 STUDY COMMITTEES 
Data and Safety Monitoring Board 
An independent Data and Safety Monitoring Board (DSMB) will monitor the accruing safety 
and outcome data. 
The DSMB will be composed of independent cardiologists, independent interventionalists 
and one independent biostatistician.   
The DSMB will review safety data regularly provided by the Leuven Safety Group (LSG). 
The DSMB will also conduct analyses of the data at the request of the Steering Committee 
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and/or Executive Committee. The DSMB analyses and operations will be formally separated 
from the sponsor, the investigators and the Steering/Executive Committee. The DSMB will 
advise the Study Chairman by giving recommendations on the trial continuation or aspects of 
the study conduct. The tasks of the DSMB will be described in detail in the DSMB charter. 
Stroke Review Panel 
An independent Stroke Review Panel will perform a final evaluation and classification of 
documented clinically suspected strokes.  
The Stroke Review Panel members will include independent neurologists and neuroradio-
logists. 
All the clinically suspected stroke events will be reviewed by the Stroke Review Panel. On 
the basis of the stroke event documentation the Stroke Review Panel will assess and classify 
each stroke event as primary haemorrhagic or ischaemic or unclassifiable.   
The classification of the strokes will be made available for the periodical DSMB reviews. 
Executive Committee 
The Executive Committee is composed of F. Van de Werf (Chairman), P. Armstrong, A. 
Gershlick (Co-Chairmen), P. Goldstein, R. Wilcox (additional members). It provides 
scientific direction of the study and assesses the study progress. The Executive Committee is 
assisted by the Steering Committee. The Executive Committee Chairman is responsible for 
communicating with the DSMB and sponsor when appropriate. 
The Executive Committee meets periodically at which occasion BI representatives may 
attend as non-voting members. 
Recommendations from the DSMB / Steering Committee will be made to the sponsor who 
will make any final decisions with regard to modifying or discontinuing the study. 
Steering Committee 
The Steering Committee is composed of the Executive Committee and members from all 
participating countries, usually the national coordinator(s) of every country. The Steering 
Committee meets periodically to assess the progress, provide scientific input and address 
policy issues and operational aspects of the protocol. BI representatives may attend these 
meetings as non-voting members. 
At the end of the trial the Steering Committee will meet in a closed session to discuss the trial 
results. The interpretation of these results will then be presented to the sponsor in a meeting 
immediately following the closed session. 
Advisory Board 
An Advisory Board composed of cardiologists, interventionalists and emergency physicians 
assists the Executive and the Steering Committee in giving recommendation regarding the 
trial protocol design and potential design adaptation or modifications recommended by the 
DSMB. 
Operations Committee 
The Operations Committee is responsible for all operational management issues in running 
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the study on a daily basis. It is composed of members with operative responsibility for 
different areas like overall management, regulatory issues, drug supply, monitoring, safety 
reporting, data management etc. It interacts closely with the Study Chairman and the 
Executive Committee, the local clinical monitors and data management for the day-to-day 
conduct of the study. 
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10. APPENDICES 
10.1 CORE LABORATORIES 
ECG Core Laboratory Edmonton 
10.2 SUB-STUDIES 
Echocardiography / Ejection fraction at 90 days 
Health-economic aspects (cost of treatment and procedures)   
A health-economic sub-study will be performed to assess the economic consequences of the 
treatment strategies being tested in the STREAM trial. Details will be laid down in a separate 
sub-study protocol. All required information will be collected in the trial eCRF. For the 
purpose of this evaluation health care resource utilisation (HCRU) data as well as health-
related quality of life data will be collected. The economic evaluation will not be part of the 
clinical trial report, and will be reported separately. 
10.3 DEFINITIONS 
10.3.1 Disabling stroke by the modified Rankin Scale 
Grade 0: no symptoms at all 
Grade 1: no significant disability despite symptoms: 
  able to carry out all usual duties and activities 
Grade 2: slight disability: 
  unable to carry out all previous activities but able to look after own affairs 
  without assistance 
Grade 3: moderate disability: 
  requiring some help but able to walk without assistance 
Grade 4: moderate severe disability: 
  unable to walk without assistance and unable to attend to own bodily needs 
  without assistance 
Grade 5: severe disability: 
  bedridden, incontinent, and requiring constant nursing care and attention 
10.3.2 Bleeds 
Major bleeds 
Severe bleed: a bleed that leads to haemodynamic compromise requiring intervention (e.g. 
blood or fluid replacement, inotropic support, ventricular assist device, surgical repair) or 
life-threatening or fatal bleeds. 
Moderate bleed: bleeding requiring transfusion of blood but which does not lead to 
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haemodynamic compromise requiring intervention. 
 
Minor bleeds 
Mild bleed: bleeding neither requiring blood transfusion nor leading to haemodynamic 
compromise. 
10.3.3 Congestive heart failure 
A positive diagnosis consists of at least one of the following conditions requiring treatment 
with diuretics: 
- Pulmonary oedema/congestion on chest x-ray without suspicion of a non-cardiac cause; 
- Rales >1/3 up from the lung base (Killip class 2 or higher); 
- Pulmonary capillary wedge pressure (PCWP) >25 mmHg; 
- Dyspnea with pO2 < 80 mmHg or O2 sat < 90 % (no supplemental O2) in the absence of 
known lung disease 
 
10.3.4 Major cardiac events 
Cardiogenic shock 
Defined as one of the following: 
1. Systolic blood pressure < 90 mmHg for at least 30 min (or the need for supportive 
measures to maintain a systolic blood pressure of > 90 mmHg) in the presence of a heart rate 
of >60 beats/min in association with signs of end organ hypoperfusion (cold extremities, low 
urinary output < 30 ml/h and/or mental confusion); 
2. A cardiac index < 2.2 l/min/m2 in the presence of a pulmonary capillary wedge pressure 
(PCWP) of >15 mmHg. 
Reinfarction 
In the first 18 hours after randomisation reinfarction is defined as: 
- recurrent signs and symptoms of ischaemia at rest, accompanied by new or recurrent 
ST-segment elevations of ≥ 0.1 mV in at least two contiguous leads lasting ≥ 30 min. 
After 18 hours reinfarction is defined as follows: 
- new Q waves (by Minnesota Code Criteria) in two or more leads and/or enzyme/ bio-
chemical evidence of reinfarction: re-elevation of CK-MB or troponin to above the 
upper limit of normal and increased by ≥ 50% over the previous value;  
- if CK-MB or troponin is not available, the total CK will be evaluated:  
- the total CK must either be re-elevated to ≥ 2 times the upper limit of normal and 
increased by ≥ 25 % or be re-elevated to ≥ 200 U/ml over the previous value;  
- if re-elevated to < 2 times the upper limit of normal, the total CK must exceed the 
upper limit of normal by ≥ 50 % and exceed the previous value by two-fold or be 
re-elevated to ≥ 200 U/ml. 
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Reinfarction after PCI is defined as: 
- CK-MB (or CK, if MB is not available) > 3 times the upper limit of normal and ≥ 50 % 
greater than the previous value and/or new Q waves (Minnesota Code) in two or more 
contiguous leads. 
Reinfarction after CABG surgery is defined as: 
- CK-MB (or CK, if MB is not available) > 5 times the upper limit of normal and ≥50% 
greater than the previous value and/or new Q waves (Minnesota Code) in two or more 
contiguous leads. 
Aborted myocardial infarction 
Combination of chest pain and transient ECG changes (≥ 50 % ST resolution) suggesting 
transmural ischaemia, and CK/CK-MB levels ≤ 2 times the upper limit of normal and/or 
troponin I/T levels corresponding to this CK/CK-MB metric within 24 hrs after randomisa-
tion. 
Refractory ischaemia 
Symptoms of ischaemia with ST-deviation or definite T-wave inversion persisting for at least 
10 min despite medical management while in-hospital and not fulfilling the diagnosis of 
infarction. 
Major arrhythmias  
Sustained ventricular tachycardia (ventricular tachycardia lasting ≥ 30 seconds or requiring 
cardioversion or causing symptoms/hypotension), ventricular fibrillation, asystole, atrial 
fibrillation, 2nd and 3rd degree atrio-ventricular block.  
Invasive procedures  
include CABG, PTCA, stent placement, intra-aortic balloon. 
Other major cardiac events 
Other major cardiac events include sustained hypotension, acute mitral regurgitation, acute 
ventricular septum defect, pericarditis, pulmonary embolism and tamponade.  
Sustained hypotension 
SBP < 90 mmHg for > 30 minutes 
Killip class 
I: The absence of rales over the lung fields and the absence of an S3. 
II: The presence of rales that do not clear with coughing, over one half or less of the lung 
fields or the presence of an S3. 
III: The presence of rales that do not clear with coughing, over more than half of the lung 
fields. 
IV: Cardiogenic shock. 
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Change 1: Adaptation of wording for trial extension 
Title (page 1 and 3) 
Comparison of the efficacy and safety of a strategy of pre-hospital fibrinolytic treatment with 
tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation 
within 6-24 hours or rescue coronary intervention versus a strategy of standard primary PCI 
in patients with acute myocardial infarction within 3 hours of onset of symptoms 
Was changed to: 
Comparison of the efficacy and safety of a strategy of early fibrinolytic treatment with 
tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation 
within 6-24 hours or rescue coronary intervention versus a strategy of standard primary PCI 
in patients with acute myocardial infarction within 3 hours of onset of symptoms 
Reason For Change 1: 
Patients presenting to the emergency department of hospitals without PCI facilities within 3 
hours of onset of STEMI may also be enrolled in STREAM, if they meet the entry criteria. 
Therefore the STREAM treatment strategy applies to both pre-hospital fibrinolytic treatment 
as well as early fibrinolytic treatment in a community hospital without PCI capacity. 
 
Change 2: Adaptation of planned trial date to account for trial extension 
Planned Dates of Trial (page 1) and Planned trial period (page 5): 
January 2008 - January 2010 
Was changed to: 
Reason For Change 2:  
January 2008 - December 2010 
Reason For Change 2: to provide time for trial implementation and recruitment in new trial 
sites  
 
Change 3: Adaptation of text for trial extension 
CLINICAL TRIAL PROTOCOL SYNOPSIS 
Objectives: In patients with acute ST-elevation myocardial infarction randomised within 3 
hours of onset of symptoms the efficacy and safety of a strategy of pre-hospital fibrinolytic 
treatment with tenecteplase and additional antiplatelet and antithrombin therapy followed by 
catheterisation within 6-24 hours or rescue coronary intervention as required will be 
compared to a strategy of primary PCI according to established local standards. 
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Diagnosis and main criteria for inclusion: Patients with acute ST-segment elevation 
myocardial infarction randomised within 3 hours of symptom onset in a pre-hospital setting 
that cannot reliably undergo primary PCI within 60 min of ECG diagnosis  
Test product(s):    Tenecteplase with concomitant antiplatelet and anticoagulant 
treatment (Group A) 
Dose and mode of admin.: Pre-hospital treatment: 
(…) 
Reference therapy: Standard primary PCI (Group B): Pre-hospital treatment: 
Was changed to: 
Objectives: In patients with acute ST-elevation myocardial infarction randomised within 3 
hours of onset of symptoms the efficacy and safety of a strategy of early fibrinolytic 
treatment with tenecteplase and additional antiplatelet and antithrombin therapy followed by 
catheterisation within 6-24 hours or rescue coronary intervention as required will be 
compared to a strategy of primary PCI according to established local standards. 
Diagnosis and main criteria for inclusion: Patients with acute ST-segment elevation 
myocardial infarction randomised within 3 hours of symptom onset in a pre-hospital setting 
or in the emergency room of hospitals without a PCI facility who cannot reliably undergo 
primary PCI within 60 min of ECG diagnosis  
Test product(s):    Tenecteplase with concomitant antiplatelet and anticoagulant 
treatment (Group A) 
Dose and mode of admin.: Pre-hospital treatment / or treatment in the emergency 
room: 
(…) 
Reference therapy: Standard primary PCI (Group B) 
Pre-hospital treatment / or treatment in the emergency room: 
Reason For Change 3: Clarification to account for enrolment of patients in the pre-hospital 
setting as well as in the emergency room of hospitals without PCI facility 
 
Change 4: Adaptation of text for trial extension 
Flowchart 
Period: Pre-hospital (incl. ambulance) 
Was changed to: 
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Period: Pre-hospital (incl. ambulance) or emergency room 
Reason For Change 4: Clarification to account for enrolment of patients in the pre-hospital 
setting as well as in the emergency room of hospitals without PCI facility 
 
Change 5: Adaptation of text for trial extension 
1.3 RATIONALE FOR PERFORMING THE TRIAL 
(…)  
The current trial will therefore evaluate the safety and efficacy of a treatment strategy 
designed to reflect optimal clinical practice that includes pre-hospital fibrinolysis and 
appropriate contemporary adjunctive medical therapy followed by coronary intervention, as 
required (‘lyse now, stent later’) (35), or primary PCI with adequate medical therapy in 
patients with STEMI presenting less than 3 hours after symptom onset.  
Was changed to: 
(…) Despite large efforts to develop and implement effective pre-hospital diagnosis and 
triage, many STEMI patients with STREAM inclusion criteria still arrive (either by 
ambulance or as walk-ins) at community hospitals. Given the anticipated delay(s) in transport 
to a PCI hospital, there is frequent uncertainty about which reperfusion therapy to commence 
on site by emergency physicians and cardiologists in community hospitals (7, 48, 49). 
Recent results and findings from the clinical trial TRANSFER-AMI and from the FAST-MI 
registry provide further support for extending the STREAM strategy to patients randomised 
in the emergency room of community hospitals, i.e. hospitals without PCI facilities.  
TRANSFER-AMI compared the outcome of a pharmaco-invasive strategy (fibrinolysis 
followed by immediate transfer to a PCI centre for routine early PCI within 6 hours) to a 
standard strategy (fibrinolysis followed by early transfer only for failed reperfusion, 
otherwise catheterisation > 24 hours) in 1,204 high-risk STEMI patients receiving 
fibrinolysis at non-PCI centres. The concomitant antithrombin medications associated with 
fibrinolysis were similar to those used in STREAM (50). The primary end point (30-day 
composite of death, reinfarction, recurrent ischaemia, new or worsening heart failure, and 
cardiogenic shock) showed that fibrinolysis at non-PCI hospitals followed by urgent transfer 
and PCI within 6 hours was associated with significantly less ischaemic complications (10.6 
% vs.16.6 %; p = 0.0013) as compared to standard therapy. There was no significant excess 
in bleeding. These results support the STREAM treatment strategy as an alternative to PCI 
also in community non-PCI hospitals (57).  
The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction 
(FAST-MI) was a French nationwide registry designed to evaluate the 'real life' management 
of patients with acute myocardial infarction. Data from 1,714 consecutive STEMI patients 
were collected over a 1-month period at the end of 2005 (51). About 60 % of the patients 
received reperfusion therapy (with primary PCI 33 % and fibrinolysis 29 %). Although two 
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thirds of patients received fibrinolysis in the pre-hospital setting, still in one third of the 
patients fibrinolysis was administered at the hospital (51).  
Overall in-hospital mortality was 5.0 % for patients who received primary PCI and 4.3 % for 
those treated with fibrinolysis (3.3 % with fibrinolysis given in the pre-hospital setting vs. 6.1 
% in hospital) (51).  
In patients receiving fibrinolysis the 30-day mortality rate was 9.2 % in those who did not 
undergo subsequent PCI as compared to 3.9 % in those who underwent PCI. Mortality was 
slightly higher (5.8 %) if PCI was symptom-driven or for rescue than for systematic PCI (2.8 
%) (51).  
For patients who received fibrinolysis in a hospital without PCI facility (n = 95) mortality at 
30 days was 4.5 % (3 out of 66) if patients underwent subsequent PCI as compared to 17 % 
(5 out of 29) without subsequent PCI (N. Danchin, personal communication, unpublished 
data from FAST-MI registry). At 12 months, survival was 93.6 % in patients receiving 
fibrinolysis (in-hospital fibrinolysis 91.5 %, pre-hospital 94.7 %), as compared to 91.8 % for 
primary PCI (p = 0.31) (51).  
These data show that in the ‘real life’ setting, the timely use of fibrinolysis followed by 
systematic PCI yields results that are similar to those of primary PCI. The STREAM 
treatment strategy therefore seems to be a valid option in early STEMI patients both in the 
pre-hospital and in-hospital setting in whom primary PCI cannot immediately be performed. 
Furthermore, the updated guidelines of ACC/AHA and the most recently published European 
Society of Cardiology’s 2008 guidelines for the treatment of ST-segment elevation 
myocardial infarction are in line with STREAM objectives and support the STREAM 
pharmaco-invasive strategy in both the pre-hospital and in-hospital setting (52, 53). 
The current trial will therefore evaluate the safety and efficacy of a treatment strategy 
designed to reflect optimal clinical practice that includes early fibrinolysis (delivered either in 
the pre-hospital setting or in the emergency room of community hospitals) and appropriate 
contemporary adjunctive medical therapy followed by coronary intervention, as required 
(‘lyse now, stent later’) (35), or standard primary PCI in patients with STEMI presenting less 
than 3 hours after symptom onset.  
Reason For Change 5: Clarification to account for enrolment of patients in the pre-hospital 
setting as well as in the emergency room of hospitals without PCI facility 
 
Change 6: Adaptation of text for trial extension 
2.1 GENERAL AIM / PRIMARY OBJECTIVE  
This study aims at evaluating, in a proof of concept approach, the outcome of pre-hospital 
patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom 
onset. Following randomisation a strategy of early (pre-hospital) tenecteplase and additional 
antiplatelet and antithrombin therapy followed by catheterisation within 6-24 hours with 
timely coronary intervention as appropriate (or by rescue coronary intervention if required) in 
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Group A will be compared to primary PCI performed according to local standards in Group 
B.  
Was changed to: 
This study aims at evaluating, in a proof of concept approach, the outcome of patients 
presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in 
either a pre-hospital setting or community hospital emergency room without a PCI facility. 
Following randomisation a strategy of early tenecteplase and additional antiplatelet and 
antithrombin therapy followed by catheterisation within 6-24 hours with timely coronary 
intervention as appropriate (or by rescue coronary intervention if required) in Group A will 
be compared to primary PCI performed according to local standards in Group B.   
Reason For Change 6: Clarification to account for enrolment of patients in the pre-hospital 
setting as well as in the emergency room of hospitals without PCI facility 
 
Change 7: Adaptation of text for trial extension 
3.1 OVERALL TRIAL DESIGN AND PLAN - DESCRIPTION  
In patients with acute ST-elevation myocardial infarction randomised within 3 hours of onset 
of symptoms the efficacy and safety of a strategy of pre-hospital fibrinolytic treatment with 
tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation 
within 6-24 hours or rescue coronary intervention as required will be compared to a strategy 
of primary PCI according to established local standards.  
Was changed to: 
In patients with acute ST-elevation myocardial infarction randomised within 3 hours of onset 
of symptoms the efficacy and safety of a strategy of early fibrinolytic treatment with 
tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation 
within 6-24 hours or rescue coronary intervention as required will be compared to a strategy 
of primary PCI according to established local standards.  
Reason For Change 7: Clarification to account for enrolment of patients in the pre-hospital 
setting as well as in the emergency room of hospitals without PCI facility 
 
Change 8: Correction of a typo 
3.2 DISCUSSION OF TRIAL DESIGN, INCLUDING THE CHOICE OF CONTROL 
GROUP(S)  
• Group A: fibrinolytic treatment with tenecteplase followed by followed by 
catheterisation within 6-24 hours or rescue coronary intervention as required.  
Was changed to: 
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• Group A: fibrinolytic treatment with tenecteplase followed by catheterisation within 
6-24 hours or rescue coronary intervention as required.  
Reason For Change 8: Deletion of repeated words 
 
Change 9: Adaptation of text for trial extension 
3.3 SELECTION OF TRIAL POPULATION 
Patients with ST-elevation acute myocardial infarction (STEMI) within 3 hours of symptom 
onset in the pre-hospital setting will be randomised to Group A for a strategy of early pre-
hospital fibrinolysis or to Group B for a strategy of primary PCI, if the eligibility criteria 
mentioned below are met. 
Approximately 2,000 patients (1,000 patients per group) will be enrolled in approximately 
100-200 sites located in Europe, Canada and other countries. 
Was changed to: 
Patients with ST-elevation acute myocardial infarction (STEMI) within 3 hours of symptom 
onset in the pre-hospital setting or emergency room of hospitals without PCI facility will be 
randomised to Group A for a strategy of early fibrinolysis or to Group B for a strategy of 
primary PCI, if the eligibility criteria mentioned below are met. 
Approximately 2,000 patients (1,000 patients per group) will be enrolled in approximately 
100-200 sites located in Europe, Canada and other countries. There will be two different 
types of sites: sites enrolling in the pre-hospital setting (i.e. by ambulance) or sites enrolling 
in the emergency room of a community hospital. 
Reason For Change 9: Clarification to account for enrolment of patients in the pre-hospital 
setting or in the emergency room of hospitals without PCI facility 
 
Change 10: Adaptation of text for trial extension 
4.1.2 Methods of assigning patients to treatment groups 
Immediately after screening, eligible patients will be randomised to one of the following 
treatment groups to achieve equal numbers of patients in each group (approx. 1,000 patients 
per group): Pre-hospital fibrinolysis, antiplatelet and antithrombin treatment followed by 
catheterisation/PCI (Group A), or antiplatelet and antithrombin treatment and subsequent 
primary PCI according to local standards (Group B).  
Was changed to: 
Immediately after screening, eligible patients will be randomised to one of the following 
treatment groups to achieve equal numbers of patients in each group (approx. 1,000 patients 
per group): Early fibrinolysis, antiplatelet and antithrombin treatment followed by coronary 
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angiography/PCI (Group A), or primary PCI according to local standards (Group B). The 
number of sites is intended to be approximately the same in each setting (pre-hospital or 
community hospital emergency room) across the trial.     
Reason For Change 10: Clarification to account for enrolment of patients in the pre-hospital 
setting as well as in the emergency room of hospitals without PCI facility and minor 
correction of wording 
 
Change 11: Adaptation of text for trial extension 
4.1.3 Selection of doses in the trial 
(…) Pre-hospital treatment will be followed by timely PCI, i.e. coronary angiography after 6 
hours but within 24 hours and, if required, stenting/percutaneous transluminal coronary 
angioplasty (PTCA) or, in case of insufficient ST resolution at 90 min, rescue PCI. The time 
window of 6-24 hours between pre-hospital fibrinolysis and catheterisation will allow for 
optimal balance between best care and resource use. 
Was changed to: 
(…) Pre-hospital or immediate in-hospital treatment in the community hospital emergency 
room will be followed by coronary angiography after 6 hours but within 24 hours of the start 
of fibrinolytic therapy and, if required, PCI or, in case of insufficient ST resolution at 90 min, 
rescue PCI. The time window of 6-24 hours between start of fibrinolysis and angiography 
avoids interventions when there is still the pro-thrombotic effect of the lytic agent on the one 
hand and, on the other hand, minimalises the risk of spontaneous reocclusion after successful 
fibrinolysis.  
Reason For Change 11: Clarification and minor corrections to account for enrolment of 
patients in the pre-hospital setting as well as in the emergency room of hospitals without PCI 
facility  
 
Change 12: Adaptation of text for trial extension 
4.1.4 Selection and timing of doses for each patient 
Acetylsalicylic acid 
Acetylsalicylic acid is expected to be administered routinely to all patients (Group A and B) 
at a dose of 150-325 mg p.o. on scene (pre-hospital) and then 75-325 mg p.o. once daily for 
at least 90 days. 
Was changed to: 
Acetylsalicylic acid is expected to be administered routinely to all patients (Group A and B) 
at a dose of 150-325 mg p.o. on scene (pre-hospital) or in the emergency room (for patients 
randomised in a community hospital) and then 75-325 mg p.o. once daily for at least 90 days. 
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Reason For Change 12: Clarification to account for enrolment of patients in the pre-hospital 
setting as well as in the emergency room of hospitals without PCI facility 
 
Change 13: Adaptation of text for trial extension and further guidance on enoxaparin 
treatment  
4.1.4.1 Group A  
Pre-hospital/ambulance treatment:  
(…) 
Note: Additional treatment with acetylsalicylic acid is recommended as per local guidelines.  
The pre-hospital use of GP IIb/IIIa inhibitors is strongly discouraged (except for bail-out 
situations).  
In-hospital treatment: 
(…) 
Enoxaparin 
If the last subcutaneous dose of enoxaparin was given more than 8 hrs before catheterisation, 
a dose of 0.3 mg/kg enoxaparin should be given intravenously. If the last subcutaneous dose 
of enoxaparin was administered within the previous 8 hrs, no additional enoxaparin should be 
given prior to catheterisation Prior to catheterisation enoxaparin should be given according to 
the following scheme (please also refer to chapter 4.2.2 for restrictions). 
(…) 
Note: For patients who received enoxaparin in the pre-hospital setting a change to a different 
type of heparin (e.g., unfractionated heparin) prior to catheterisation should be avoided (cf. 
4.2.2).  
Clopidogrel 
(…) 
Was changed to: 
Pre-hospital/ambulance treatment or treatment in the emergency room:  
(…) 
Note: Additional treatment with acetylsalicylic acid is recommended as per local guidelines.  
The use of GP IIb/IIIa inhibitors in pre-hospital setting or emergency room is strongly 
discouraged (except for bail-out situations).  
In-hospital treatment: 
(…) 
Enoxaparin 
Prior to catheterisation enoxaparin should be given according to the following scheme (please 
also refer to chapter 4.2.2 for restrictions) (28, 54, 55, 56):  
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< 75 years:  
- If catheterisation is performed 0 – 8 hrs after randomisation, i.e. after the first 
subcutaneous enoxaparin dose but prior to the second, no additional antithrombotic therapy 
should be given.  
- If catheterisation is performed > 8 hours from the most recent subcutaneous enoxaparin 
dose, additional 0.3 mg/kg of intravenous enoxaparin should be administered.  
≥ 75 years: 
- All patients ≥ 75 years who received 0.75 mg/kg of subcutaneous enoxaparin at 
randomisation should receive supplemental 0.3 mg/kg of intravenous enoxaparin at the 
time of catheterisation, if it occurs prior to the second dose of subcutaneous enoxaparin. 
- If catheterisation is performed > 8 hours from the second or any later subcutaneous 
enoxaparin dose, additional 0.3 mg/kg of intravenous enoxaparin should be 
administered.  
(…) 
Note: For patients who received enoxaparin in the pre-hospital setting or a community 
hospital emergency room a change to a different type of heparin (e.g., unfractionated heparin) 
prior to catheterisation should be avoided (cf. 4.2.2).  
Clopidogrel 
Irrespective of any age, an additional 300 mg loading dose of clopidogrel (but NOT 600 mg) 
is permitted at the time of catheterisation whenever it occurs (i.e., planned within 6-24 hrs 
after fibrinolysis or because of rescue or urgent PCI).  
(…) 
Reason For Change 13: Clarification to account for enrolment of patients in the pre-hospital 
setting as well as in the emergency room of hospitals without PCI facility; further guidance 
on treatment with enoxaparin and clopidogrel in case of catheterisation has been provided 
 
Change 14: Adaptation of text for trial extension 
4.1.4.2 Group B  
Pre-hospital treatment:  
Was changed to: 
Pre-hospital treatment or treatment in the emergency room: 
Reason For Change 14: Clarification to account for enrolment of patients in the pre-hospital 
setting as well as in the emergency room of hospitals without PCI facility 
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Change 15: Addition of a supplemental device 
4.1.6 Packaging, labelling, and re-supply 
Contents of treatment box for Group A: 
The following was added: 
- 2 Unisafe filter spikes for enoxaparin vials 
Reason For Change 15: The use of filter spikes for re-closure of the enoxaparin vial is 
recommended in the Summary of Product Characteristics by the manufacturer of enoxaparin 
in order to keep the solution stable, i.e. avoid contamination 
 
Change 16: Adaptation of text for trial extension 
4.2.2 Restrictions  
Enoxaparin and heparin  
Patients who received enoxaparin in the pre-hospital setting should not be administered a 
different type of heparin prior to catheterisation (and vice versa). If heparin was used in the 
pre-hospital setting or early in-hospital period, subsequent treatment should not be switched 
to enoxaparin prior to catheterisation.  
Was changed to: 
Patients who received enoxaparin in the pre-hospital setting or emergency room should not 
be administered a different type of heparin prior to catheterisation (and vice versa). If heparin 
was used in the pre-hospital setting or early in-hospital period, subsequent treatment should 
not be switched to enoxaparin prior to catheterisation.  
Reason For Change 16: Clarification to account for enrolment of patients in the pre-hospital 
setting as well as in the emergency room of hospitals without PCI facility 
 
Change 17: Adaptation of text for trial extension 
5. OBSERVATIONS 
All observations that represent or contribute to a trial endpoint are listed in the Trial Flow 
Chart on page 9. Observations will be taken during different trial periods: the pre-hospital 
(including ambulance) period, the in-hospital period, hospital discharge, end of trial (30 days) 
and the follow-up period (1-year), respectively, as described below. 
Was changed to: 
All observations that represent or contribute to a trial endpoint are listed in the Trial Flow 
Chart on page 9. Observations will be taken during different trial periods: the pre-hospital 
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(including ambulance) or emergency room period, the in-hospital period, hospital discharge, 
end of trial (30 days) and the follow-up period (1-year), respectively, as described below. 
Reason For Change 17: Clarification to account for enrolment of patients in the pre-hospital 
setting as well as in the emergency room of hospitals without PCI facility 
 
Change 18: Clarification  
5.2.1 General assessment of safety 
- Adverse events: 
(…) The following adverse events are expected as disease-related events (i.e. related to acute 
myocardial infarction): 
Arrhythmias 
All arrhythmias occurring later than 3 hours after fibrinolysis 
Was changed to: 
- Adverse events: 
(…) The following adverse events are expected as disease-related events (i.e. related to acute 
myocardial infarction): 
Arrhythmias 
All arrhythmias occurring later than 3 hours after fibrinolysis 
All arrhythmias in patients who did not receive fibrinolysis 
Reason For Change 18: As fibrinolysis is not given in Group B, the general reference to 
fibrinolysis and the associated timeline for potential trial drug effect does not apply. As a 
consequence the wording needs to be adapted to account for patients who did not receive 
fibrinolysis.  
 
Change 19: Adaptation of text for trial extension 
6. INVESTIGATIONAL PLAN 
Prerequisites:  
During the site selection process the qualification of a trial site for participation in the trial 
has to be determined. Sites must be experienced in pre-hospital fibrinolysis and have access 
to a catheterisation laboratory or cooperate with hospitals that provide or have access to a 
catheterisation laboratory to ensure the performance of delayed or rescue PCI, as required 
(Group A), or of primary PCI (Group B) according to the protocol.  
Before a trial site commences active participation in the trial, the composition of the 
ambulance staff involved in pre-hospital trial procedures should be clearly established. (…) 
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In addition, study medication logistics and associated procedures (including storage at 
hospital (pharmacy), interim storage in the ambulance, timely re-supply between hospital 
(pharmacy) and ambulance, transfer of used trial kits to hospital, etc.) must also be defined 
and documented before any site starts patient enrolment.  
Was changed to: 
During the site selection process the qualification of a trial site for participation in the trial 
has to be determined. Sites must be experienced in pre-hospital fibrinolysis and have access 
to a catheterisation laboratory or cooperate with hospitals that provide or have access to a 
catheterisation laboratory (e.g., by hub and spoke relationship) to ensure the performance of 
delayed or rescue PCI, as required (Group A), or of primary PCI (Group B) according to the 
protocol (cf. Appendix 10.3.5). Each site enrolling patients will be assigned an individual site 
number and IVRS code.  
Whenever a patient can be randomised in the pre-hospital setting (i.e. by ambulance staff), 
randomisation should not be delayed in order to randomise the patient in the emergency room 
of a community hospital. 
Before a trial site enrolling patients in the pre-hospital setting commences active participation 
in the trial, the composition of the ambulance staff involved in pre-hospital trial procedures 
should be clearly established. (…) 
In addition, study medication logistics and associated procedures (including storage at 
hospital (pharmacy), interim storage in the ambulance or emergency room, timely re-supply 
between hospital (pharmacy) and ambulance or emergency room, transfer of used trial kits to 
PCI hospital, etc.) must also be defined and documented before any site starts patient 
enrolment. 
Reason For Change 19: Clarification to account for enrolment of patients in the pre-hospital 
setting as well as in the emergency room of hospitals without PCI facility 
 
Change 20: Adaptation of text for trial extension 
6.1 VISIT SCHEDULE  
The trial consists of the following periods:  
− Pre-hospital period: screening/baseline assessments, informed consent, randomisation, 
pre-hospital treatment  
Was changed to: 
− Pre-hospital period or emergency room: screening/baseline assessments, informed 
consent, randomisation, early study treatment 
Reason For Change 20: Clarification to account for enrolment of patients in the pre-hospital 
setting as well as in the emergency room of hospitals without PCI facility  
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Change 21: Adaptation of text for trial extension 
6.2 TRIAL PROCEDURES AT EACH VISIT  
6.2.1 Pre-hospital period  
All patients will be screened, enrolled and receive treatment during the pre-hospital period. 
As soon as the ambulance arrives at the scene, the patient will be screened for eligibility by 
the investigator or authorised ambulance staff. Routine and/or rescue procedures are 
performed according to local practice and established guidelines. The following assessments 
will be done (for details of the individual assessments please refer to the Flow Chart on page 
9 and to section 5.2). (…) 
The following documents/samples should accompany the patient when transferred to the 
receiving hospital:  
Was changed to: 
6.2.1 Pre-hospital period or emergency room 
In sites enrolling patients in the pre-hospital setting, patients will be screened, enrolled and 
receive treatment during the pre-hospital period. As soon as the ambulance arrives at the 
scene, patients will be screened for eligibility and enrolled by the investigator or authorised 
ambulance staff. In sites enrolling patients in the emergency room (cf. Appendix 10.3.5), 
patients will be screened, enrolled and receive treatment in the emergency room. In each 
setting routine and/or rescue procedures are performed according to local practice and 
established guidelines. The following assessments will be done (for details of the individual 
assessments please refer to the Flow Chart on page 9 and to section 5.2). (…) 
The following documents/samples should accompany any pre-hospital patient when 
transferred to the receiving hospital:  
Reason For Change 21: Clarification to account for enrolment of patients in the pre-hospital 
setting as well as in the emergency room of hospitals without PCI facility 
 
Change 22: Adaptation of text for trial extension 
6.2.2 In-hospital period (including discharge)  
The in-hospital period starts with the patient’s arrival at the hospital.  
Was changed to: 
For patients randomised in the pre-hospital setting, the in-hospital period starts with the 
patient’s arrival at the hospital. For patients randomised in the emergency room, the in-
hospital period starts as soon as the patient has received the early study treatment and/or 
leaves the emergency room. 
Reason For Change 22: Clarification to account for enrolment of patients in the pre-hospital 
setting as well as in the emergency room of hospitals without PCI facility 
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Change 23: Adaptation of text for trial extension 
Table 4: Overview of ECG measurements in Group A and Table 5: Overview of ECG 
measurements in Group B 
 
Was changed to: 
 
Reason For Change 23: Clarification to account for enrolment of patients in the pre-hospital 
setting as well as in the emergency room of hospitals without PCI facility 
 
Change 24: Adaptation of text for trial extension 
7.3.1  Subgroup analysis 
The usual subgroups as predefined in the ASSENT II / III publications will be analysed 
descriptively (25, 26). 
Was changed to: 
The usual subgroups as predefined in the ASSENT-2 / 3 / 3+ and ASSENT-4 PCI 
publications will be analysed descriptively (10, 16, 25, 26). 
Reason For Change 24: to include subgroup analyses for patients enrolled in the pre-hospital 
setting as well as in the emergency room of hospitals without PCI facility 
 
 
 
 
Timing of ECG  Location  Reason for ECG  
Baseline  Pre-hospital:  
on site/ambulance  
ECG for assessment of STEMI entry 
criteria  
Timing of ECG  Location  Reason for ECG  
Baseline  Pre-hospital:  
on site/ambulance  
or emergency room 
ECG for assessment of STEMI entry 
criteria  
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Change 25: Addition of references 
9.1 PUBLISHED REFERENCES 
The following was added: 
48. Le May MR, So DY, Dionne R, et al. A citywide protocol for primary PCI in ST-segment 
elevation myocardial infarction. NEJM 2008;358:231-240. (P08-01218)  
49. Henry TD, Sharkey SW, Burke MN, et al. A regional system to provide timely access to 
percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation 
2007;116:721-728. (P07-10683) 
50. Cantor WJ, Fitchett D, Borgundvaag B, et al. Rationale and design of the Trial of Routine 
ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial 
Infarction (TRANSFER-AMI). Am Heart J. 2008;155:19-25. (P08-02032) 
51. Danchin N, Coste P, Ferrières J, et al. Comparison of thrombolysis followed by broad use 
of percutaneous coronary intervention with primary percutaneous coronary intervention for 
ST-segment-elevation acute myocardial infarction. Data From the French Registry on Acute 
ST-Elevation Myocardial Infarction (FAST-MI). Circulation 2008;118:268-276. (P08-10558) 
52. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous 
coronary intervention: A report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr et 
al. J Am Coll Cardiol 2008;51:172-209. (P08-01657) 
53. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in 
patients presenting with persistent ST-segment elevation. The Task Force on the Management 
of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 
2008;29:2909-2945. (P08-14487) 
54. Buller CE, Pate GE, Armstrong PW, et al. Catheter thrombosis during primary 
percutaneous coronary intervention for acute ST elevation myocardial infarction despite 
subcutaneous low molecular weight heparin, acetyl salicylic acid, clopidogrel and abciximab 
pretreatment. Can J Cardiol 2006;22:511-515. (P09-0574) 
55. Welsh RC, Gordon P, Westerhout CM, et al. A Novel Enoxaparin Regime for ST 
Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary 
Intervention: A WEST Sub-study. Catheter Cardiovasc Interv 2007;70:341-348. (P09-0573) 
56. Welsh RC Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI 
patients treated with TNK.Can J Cardiol 2007;23:Abstr 271C. (P09-02136) 
Reason For Change 25: Important recent literature has been added 
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Change 26: Addition of references 
9.2 UNPUBLISHED REFERENCES 
The following was added: 
57. Cantor WD. TRANSFER-AMI. Presentation as a Late-Breaking Clinical Trial at the 
American College of Cardiology 57th Annual Scientific Session, Chicago, March 31, 2008 
Reason For Change 26: Important recent literature has been added 
 
Change 27: Addition of an appendix 
10. APPENDICES  
The following was added: 
10.3.5 Community hospitals 
A community hospital is defined as any hospital capable of admitting an acute coronary care 
patient that does not have PCI capabilities on site. 
Reason For Change 27: to define hospitals without PCI facility where patients can be enrolled 
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Change 1: Adaptation of dose of tenecteplase for elderly patients in Group A 
CLINICAL TRIAL PROTOCOL SYNOPSIS and Chapter 4.1.4.1 Group A 
Pre-hospital treatment / or treatment in the emergency room: 
Tenecteplase 
50 mg of drug reconstituted in 10 ml sterile water for injection will be given as single weight-
adjusted i.v. bolus over 5 - 10 seconds 
Weight (kg)   Dose (mg)   Dose (ml) 
≥55 to <60   30 mg      6 ml 
≥60 to <70   35 mg      7 ml 
≥70 to <80   40 mg      8 ml 
≥80 to <90   45 mg      9 ml 
≥90    50 mg    10 ml 
 
Was changed to: 
Pre-hospital treatment / or treatment in the emergency room: 
Tenecteplase 
50 mg of drug reconstituted in 10 ml sterile water for injection will be given as single weight-
adjusted i.v. bolus over 5 - 10 seconds according to the following scheme: 
< 75 years: 
Weight (kg)   Dose (mg)   Dose (ml) 
≥55 to <60   30.0 mg     6.0 ml 
≥60 to <70   35.0 mg     7.0 ml 
≥70 to <80   40.0 mg     8.0 ml 
≥80 to <90   45.0 mg     9.0 ml 
≥90    50.0 mg   10.0 ml 
 
≥75 years: 
Weight (kg)   Dose (mg)   Dose (ml) 
≥55 to <60   15.0 mg     3.0 ml 
≥60 to <70   17.5 mg     3.5 ml 
≥70 to <80   20.0 mg     4.0 ml 
≥80 to <90   22.5 mg     4.5 ml 
≥90    25.0 mg     5.0 ml 
 
Reason For Change 1:  
A higher than expected rate of ICH was observed in elderly patients in Group A. Despite 
small numbers and wide confidence limits, the STREAM Executive Committee in 
conjunction with the Chair of the Data Safety Monitoring Board recommend this change. 
This strategy has been used successfully by Henry et al. (49). Given that ECG at 90 minutes 
and rescue PCI, if appropriate, are already part of the STREAM strategy for group A it was 
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felt that this change would provide an optimal balance between efficacy and safety. In order 
to prevent potential hazard, this change is to be implemented immediately.   
 
Change 2: Change of ECG-associated inclusion criterion 
CLINICAL TRIAL PROTOCOL SYNOPSIS and Chapter 3.3.1 
Inclusion criteria 
(...) 
3. 12-lead ECG indicative of an acute STEMI (ST-elevation will be measured from the J 
point; scale: 1 mm per 0.1 mV): 
≥ 2 mm ST-elevation across 2 contiguous precordial leads (V1-V6) or leads I and aVL for 
a minimum combined total of ≥ 4 mm ST-elevation  
or 
≥ 3 mm ST-elevation in 2 contiguous inferior leads (II, III, aVF) for a minimum combined 
total of ≥ 6 mm ST-elevation    
Was changed to: 
Inclusion criteria 
(...) 
3. 12-lead ECG indicative of an acute STEMI (ST-elevation will be measured from the J 
point; scale: 1 mm per 0.1 mV): 
≥ 2 mm ST-elevation across 2 contiguous precordial leads (V1-V6) or leads I and aVL for 
a minimum combined total of ≥ 4 mm ST-elevation  
or 
≥ 2 mm ST-elevation in 2 contiguous inferior leads (II, III, aVF) for a minimum combined 
total of ≥ 4 mm ST-elevation    
Reason For Change 2: 
About one third of patients with inferior STEMI, who are in principal eligible for clinical 
reperfusion therapy, cannot be included in STREAM because of the stringent ECG entry 
criteria. Widening of these criteria would therefore make it possible to also enrol patients 
with slightly smaller inferior infarctions. A minimum of ≥ 2 mm elevation in 2 contiguous 
inferior leads or even less was used as an ECG entry criterion in previous key studies in the 
same setting as STREAM, namely CAPTIM (6), WEST (11), ASSENT 3+ (10), and 
TRANSFER-AMI (57). All these studies have suggested the outcome potential of the 
STREAM therapeutic strategy and also reflect current practice of reperfusion therapy. In 
addition, from a practical point of view, this change will simplify the ECG criteria and make 
selection easier, as the required ST-elevation per lead as well as the minimum combined total 
will be similar for precordial and inferior leads. 
This change is to be implemented only after documented approval of the IRB / IEC / 
Competent Authorities. 
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Change 3: Adaptation of text to reflect change of dose 
1.4 BENEFIT / RISK ASSESSMENT 
(…) In elderly patients, who are known to have an increased bleeding risk (36), the initial 
loading dose of clopidogrel as well as the initial bolus of enoxaparin will be omitted to 
conform to the evidence-based strategy of the COMMIT and ExTRACT trials (28, 20, 32) 
which support this approach as safe and effective (please refer to section 1.2 and 4.1.3). 
Was changed to: 
(…) In elderly patients, who are known to have an increased bleeding risk (36), half-dose 
tenecteplase will be used (49) and the initial loading dose of clopidogrel as well as the initial 
bolus of enoxaparin will be omitted to conform to the evidence-based strategy of the 
COMMIT and ExTRACT trials (28, 30, 32) which support this approach as safe and effective 
(please refer to sections 1.2 and 4.1.3). 
Reason For Change 3: cf. reason for Change 1  
 
Change 4: Correction of an error 
4.1.1 Identity of investigational product(s) 
Tenecteplase (Metalyse®) manufactured by Boehringer Ingelheim, will be provided as 50 mg 
sterile, lyophilized powder in a vial for reconstitution with a 10 ml pre-filled syringe of sterile 
water for i.v. injection. Each vial contains 50 mg of tenecteplase and excipients: L-arginine, 
phosphoric acid and polysorbate 80. 
Was changed to: 
Tenecteplase (Metalyse®) manufactured by Boehringer Ingelheim, will be provided as 50 mg 
sterile, lyophilized powder in a vial for reconstitution with a 10 ml pre-filled syringe of sterile 
water for i.v. injection. Each vial contains 50 mg of tenecteplase and excipients: L-arginine, 
phosphoric acid and polysorbate 20. 
Reason For Change 4:   
Polysorbate 20 is used as excipient as described in the Summary of Product Characteristics.  
 
Change 5: Adaptation of text to reflect change of dose 
4.1.3 Selection of doses in the trial 
Tenecteplase is given in a weight-adjusted dose regimen as described in the following section 
(4.1.4) according to the Basic Product Information (46).  
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(…) 
As for the sequence of treatments, full dose tenecteplase administered as a single intravenous 
bolus over 5-10 seconds should be the first drug injected. The initial enoxaparin intravenous 
bolus of 30 mg is then to be administered via the same i.v. line after flushing. Then the two 
oral drugs, clopidogrel and acetylsalicylic acid should be given.  
Was changed to: 
4.1.3 Selection of doses in the trial 
Tenecteplase is given in a weight-adjusted dose regimen as described in the following section 
(4.1.4) according to the Basic Product Information (46). Based on the strategy used by Henry 
et al. (49) and after balancing the risks versus benefits the dose has been adapted for patients 
≥ 75 years of age who will receive half dose tenecteplase. As described below, the strategy of 
measuring ST-segment resolution at 90 minutes after fibrinolysis and performing rescue PCI, 
if appropriate, in Group A is considered to provide an optimal balance between efficacy and 
safety. 
(…) 
As for the sequence of treatments, the required dose of tenecteplase administered as a single 
intravenous bolus over 5-10 seconds should be the first drug injected. The initial enoxaparin 
intravenous bolus of 30 mg is then to be administered via the same i.v. line after flushing. 
Then the two oral drugs, clopidogrel and acetylsalicylic acid should be given.  
Reason For Change 5: cf. reason for Change 1  
 
Change 6: Addition of references and emphasis of associated risks 
4.2.2 Restrictions 
Enoxaparin and heparin 
Patients who received enoxaparin in the pre-hospital setting or emergency room should not 
be administered a different type of heparin prior to catheterisation (and vice versa). If heparin 
was used in the pre-hospital setting or early in-hospital period, subsequent treatment should 
not be switched to enoxaparin prior to catheterisation. 
Prior to catheterisation a dose of 0.3 mg/kg i.v. enoxaparin should be given to patients in 
Group A, unless the last subcutaneous dose of enoxaparin was given within the previous 8 hrs.  
Was changed to: 
4.2.2 Restrictions 
Enoxaparin and heparin 
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Patients who received enoxaparin in the pre-hospital setting or emergency room should not 
be administered a different type of heparin prior to catheterisation (and vice versa) as this 
may result in excessive anticoagulation well above therapeutic levels (56, 58). If heparin was 
used in the pre-hospital setting or early in-hospital period, subsequent treatment should not be 
switched to enoxaparin prior to catheterisation. 
Prior to catheterisation a dose of 0.3 mg/kg i.v. enoxaparin should be given to patients in 
Group A, unless the last subcutaneous dose of enoxaparin was given within the previous 8 hrs 
(56).  
Reason For Change 6: Important recent literature has been incorporated 
 
Change 7: Addition of references 
9.1 PUBLISHED REFERENCES 
The following was added: 
57. Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis 
for acute myocardial infarction. N Engl J Med 2009;360:2705-2718. (P09-08383) 
58. Drouet L, Bal dit Sollier C, Martin J. Adding intravenous unfractionated heparin to 
standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: 
Results of the STACK-on to ENOXaparin (STACKENOX) study. Am Heart J 2009;158:177-
184. (R09-4327) 
Reason For Change 7: Important recent literature has been added 
 
Change 8: Deletion of a reference 
9.2 UNPUBLISHED REFERENCES 
The following was deleted: 
57. Cantor WD. TRANSFER-AMI. Presentation as a Late-Breaking Clinical Trial at the 
American College of Cardiology 57th Annual Scientific Session, Chicago, March 31, 2008 
Reason For Change 8:  
This unpublished reference has been replaced by the corresponding published reference of the 
same author (cf. Change 7) 
1.c   Summary of changes to the Original Protocol Sep 25, 2007 
Amendment 1 – Feb 19, 2009 
1. Extension of study to community hospitals 
2. Minor clarifications 
Amendment 2 – Aug 24, 2009: 
1. Adaptation of dose of tenecteplase for elderly patients in Group A 
2. Modification of inclusion criterion 3 to widen ECG entry criteria 
3. Minor corrections and supplementations 
Amendment 3 – Dec 2, 2010 
1. Adaptation of planned trial date/extension of study period (trial period: Jan 2008‐Apr 2012) 
2. Minor corrections for clarification 
Amendment 4 – Dec 22, 2011 
1. Adaptation of planned trial date/extension of study period (trial period: Jan 2008‐Aug 2012) 
   
2a. DraftStatistical Analysis plan 
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INTRODUCTION 
This statistical analysis plan for STREAM contains the following: 
• 1. Statistical design/model of the study 
• 2.   Definition of the analysis populations 
• 2. Handling of missing data  
• 3. Statistical methods  
• 4.  Tables and Figures 
 
1. STATISTICAL DESIGN/MODEL 
The trial is a prospective, multi-centre, international, randomised (1:1), open-label, 
parallel-group comparison, conducted for investigating, in a proof of concept 
approach, the efficacy and safety of 
A. Tenecteplase + enoxaparin + clopidogrel (experimental, Group A) 
B. Primary PCI according to local standards (reference, Group B) 
in patients with acute myocardial infarction randomised < 3 hours from symptom 
onset. 
The study is exploratory in nature and the principal aim of the trial is to evaluate the 
safety and efficacy in the treatment groups measured by single and composite 
endpoints as listed in sections 4.2 to 4.4. 
No confirmatory statistical hypothesis test is pre-specified. All statistical tests are of 
exploratory nature for formal statistical hypotheses generation. All statistical 
analyses will be done by presenting confidence intervals and descriptive p-values. 
 
2. DEFINITION OF THE ANALYSIS POPULATIONS 
The two analysis populations are defined as follows: 
1. Intent-to-treat (ITT) population:  based on randomized treatment 
Subjects will be analysed according to the treatment group to which they 
were randomized, irrespective of which study treatment was given or if any 
study treatment was received. 
 
2. Per Protocol (PP) population:  Based on all randomized patients. 
If a subject has one or more of the following major protocol 
violations/deviations, the subject will be excluded from the population: 
To be defined 
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3. HANDLING OF MISSING DATA 
Best efforts will be made to collect complete data for the clinical endpoints of 
interest, regardless of whether or not the subject received study drug. 
All percentages will be calculated on the number of subjects with non-missing 
information. 
 
3.1 ENDPOINTS 
It is anticipated that data will be available for at least 99% of the patients on the 
following endpoints: 30-day mortality, cardiogenic shock within 30 days, congestive 
heart failure within 30 days respectively. Therefore no imputation of these endpoints 
will be applied.   
In the unlikely case that the regular data quality review meetings (DQRMs) would 
indicate that the data availability of 99% might not be reached, the primary efficacy 
and safety analysis will be reconsidered and the statistical analysis plan (TSAP) will 
be adapted accordingly. 
For the other clinical endpoints, it is anticipated that data will be available for at 
least 95% of the patients. Also no imputation of these endpoints will be applied. 
 
3.2 COVARIATES 
No imputations will be used for the missing covariates. 
 
4. STATISTICAL METHODS 
Statistical analysis will be programmed using the SAS® system version 9.1.3. 
 
In the methodology described below, the null hypothesis of no difference between 
treatments will in many cases be evaluated both by means of a Fisher’s Exact test 
and the 95% confidence interval for the relative risk.  Even though both methods 
are asymptotically equivalent, for a finite sample there is a small probability that 
they do not yield the same conclusion regarding the rejection of the null hypothesis. 
 
4.1 BASELINE CHARACTERISTICS 
For the continuous variables, the mean, standard deviation (SD), median, and 
range will be reported in each treatment group and a t-test will be used.  For the 
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discrete variables, the number of subjects in each category and the percentage with 
respect to the number of subjects with non-missing information for that item will be 
reported in each treatment group.  A chi-square test for an r x 2 contingency table 
will be performed for all categorical variables. 
P-values for baseline characteristics will be calculated only for descriptive purposes. 
4.2 EFFICACY ENDPOINTS 
The following observations are considered as endpoints evaluating the efficacy and 
will be assessed at day 30. They are ordered according to medical importance in 
the indication acute myocardial infarction. 
- All cause mortality 
- Cardiogenic shock 
- Recurrent myocardial infarction (reinfarction) 
- Congestive heart failure (CHF) 
- Death and shock 
- Death and shock and reinfarction  
- Death and shock and CHF 
- Death and shock and CHF and reinfarction 
- Rehospitalisation for cardiac reasons 
- Rehospitalisation for non-cardiac reasons 
The single and composite efficacy endpoints will be analyzed by presenting the 
event rates and the 95% confidence intervals (two-sided), separately for each 
treatment group. In addition, the two treatment groups will be compared by a 
Fisher’s Exact test. Also the between group comparison will be done by presenting 
the relative risk with a 95% confidence interval (two-sided). 
 
As secondary analysis, a covariate adjusted logistic effects model will be fitted for 
the two most important endpoints i.e. 30-day mortality or 30-day mortality and 
cardiongenic shock as dependent variable and treatment group as independent 
variable. Additionally, possible important predictors such as gender, age, body 
weight, infarct location (anterior or other), previous infarction, killip class, heart rate, 
systolic blood pressure and time-to-treatment will be used. The odds ratio for the 
treatment effect together with a 95% confidence interval (two-sided) will be 
reported. 
Other potentially prognostic factors will be explored and utilized as further 
covariates in the odds-ratio analysis.  
 
Statistical Analysis Plan:  TNK-tPA  Page 7 
1123.28:  STREAM Draft version 1  6 March 2008 
Being an explorative trial (a proof of concept trial) and no confirmatory statistical 
hypothesis test pre-specified, it should be noted that not all endpoints have the 
same probability of demonstrating a potential benefit for one of the treatment 
groups. The power to show a significant difference depends on the incidence rates. 
Based on the anticipated incidence rates (given between brackets) for the different 
endpoints, the efficacy endpoints are orderd as follows for showing any potential 
significant difference of a given size between the two treatment groups.  
- Rehospitalisation for cardiac reasons (2%) 
- Rehospitalisation for non-cardiac reasons (2%) 
- Cardiogenic shock (3%) 
- Recurrent myocardial infarction (reinfarction) (3%) 
- All cause mortality (4%) 
- Death and shock (5.5%) 
- Congestive heart failure (CHF) (6%) 
- Death and shock and CHF (11%) 
- Death and shock and reinfarction (13%) 
- Death and shock and CHF and reinfarction (15%) 
 
Furthermore, p-values are given for descriptive purposes only. Due to the many 
endpoints of interests, one should be aware of the multiple testing problem (control 
of the type I error). Findings should be interpreted in terms of generating 
hypotheses for future trials. In order to claim a significant finding, an appropriate 
correction for multiple testing will be performed. 
 
4.3 SAFETY ENDPOINTS 
The following observations are considered as endpoints evaluating the safety and 
will be assessed at 30 days. They are ordered according to medical importance in 
the indication acute myocardial infarction. 
 
- Total fatal stroke 
- Total disabling stroke 
- Total non-disabling stroke 
- Intracranial haemorrhage 
- Ischaemic stroke 
- Total stroke (all types) 
- Major non-intracranial bleeds including blood transfusions 
- Minor non-intracranial bleeds 
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- Total non-intracranial bleeds  
- Serious resuscitated ventricular fibrillation 
- Serious repeat target vessel recanalisation 
 
The single safety endpoints will be analyzed by presenting the event rates and the 
95% confidence intervals (two-sided), separately for each treatment group. In 
addition, the two treatment groups will be compared by a Fisher’s Exact test. Also 
the between group comparison will be done by presenting the relative risk with a 
95% confidence interval (two-sided). 
 
Being an explorative trial (a proof of concept trial)  and no confirmatory statistical 
hypothesis test pre-specified, it should be noted that not all endpoints have the 
same probability of demonstrating a potential benefit for one of the treatment 
groups. The power to show a significant difference depends on the incidence rates. 
Based on the anticipated incidence rates (given between brackets) for the different 
endpoints, the efficacy endpoints are orderd as follows for showing any potential 
significant difference of given size between the two treatment groups.  
- Total disabling stroke (0.4 %) 
- Total non-disabling stroke (0.4%) 
- Ischaemic stroke (0.7%) 
- Total fatal stroke (0.8 %) 
- Intracranial haemorrhage (0.9%) 
- Serious resuscitated ventricular fibrillation (<1 %) 
- Total stroke (1.6 %) 
- Blood transfusions (3%) 
- Major non-intracranial bleeds  (4 %)  
- Serious repeat target vessel recanalisation (4%) 
- Minor non-intracranial bleeds  (20 %)  
- Total non-intracranial bleeds  (24 %)  
 
Furthermore, p-values are given for descriptive purposes only. Due to the many 
endpoints of interests, one should be aware of the multiple testing problem (control 
of the type I error). Findings should be interpreted in terms of generating 
hypotheses for future trials. In order to claim a significant finding, an appropriate 
correction for multiple testing will be performed. 
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4.4 MIXED (EFFICACY AND SAFETY) COMPOSISTE ENDPOINTS WITHIN 30 DAYS 
- Death and non-fatal stroke 
- Death and shock and CHF and reinfarction and disabling stroke 
 
The combined efficacy and  safety endpoints will be analyzed by presenting the 
event rates and the 95% confidence intervals (two-sided), separately for each 
treatment group. In addition, the two treatment groups will be compared by a 
Fisher’s Exact test. Also the between group comparison will be done by presenting 
the relative risk with a 95% confidence interval (two-sided). 
 
Furthermore, p-values are given for descriptive purposes only. Due to the many 
endpoints of interests, one should be aware of the multiple testing problem (control 
of the type I error). Findings should be interpreted in terms of generating 
hypotheses for future trials. In order to claim a significant finding, an appropriate 
correction for multiple testing will be performed. 
 
4.5 OTHER EVALUATIONS 
A. Evaluations within 30 days 
- Duration of stay in CCU/ICU 
- Duration of initial stay in hospital 
- Duration of rehospitalisation started until and including day 30 
- Coronary perfusion pre-/post-PCI  
The different durations will be summarized with descriptive statistics (median, 
quartiles, minimum and maximum) and compared between the two treatment 
groups by a wilcoxon test. 
The analyses of the duration of stay in CCU/ICU and the durtation of initial stay 
in hospital will be performed for in-hospital survivors only and for all patients 
including those that died in-hospital. For the latter case, the durations for the 
patients who died in-hospital will be imputed by the maximum of the durations 
observed among the survivors. 
The analysis of the duration of rehospitalisation started until and including day 
30 will be performed for patients that had a rehospitalisation up to day 30. 
Coronary perfusion pre-/post-PCI will be summarized by the number of subjects 
in each category and the percentage with respect to the number of subjects with 
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non-missing information for that item will be reported in each treatment group.  A 
chi-square test for an 4 x 2 contingency table will be performed. 
B. Evaluations at 1 year  
- All-cause mortality 
- Rehospitalisation (cause of rehospitalisation) 
Time-to event analyses (Kaplan-Meier) will be performed for all cause mortality. 
The time to death from randomization (in days) will be used as time variable. In 
case no event is present, the last time the patient was seen will be used as 
censoring time. 
The frequency and causes of rehospitalisation will be analyzed descriptively. 
 
C. Evaluations specific for Group A  
- ST resolution 90 min after injection of tenecteplase 
- Incidence of aborted myocardial infarction 
- Need for rescue PCI/revascularisation (as determined by investigator)  
- Need for rescue PCI/revascularisation (centrally adjudicated)  
The above endpoints based on the ECG evaluation  will be analyzed under the 
responsibility of Prof. P. Armstrong at Edmonton, Canada. 
 
4.6 ADDITIONAL IN-HOSPITAL EVENTS  
- Major arrhythmias 
- EMD  
- Cardiac rupture 
- Acute ventricle septum defect  
- Pericarditis 
- Tamponade  
- Sustained hypotension 
- Recurrent myocardial ischemia  
- Abrupt vessel closure 
- Coronary spasm 
- Coronary arterial dissection 
- Hypersensitivity 
- Anaphylactoid reaction 
- Thrombocytopenia  
- Drop of hemoglobin > 5g/L 
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- PCI (after study PCI) 
- CABG (after study catheterisation / study PCI) 
 
The number of subjects in each category and the percentage with respect to the 
number of subjects for that item will be reported in each treatment group. Fisher’s 
Exact test will be performed. 
 
4.7 SUBGROUP ANALYSES 
Subgroup analyses will be done for 30-day mortality and recurrent myocardial 
infarction only. 
Subgroups: 
Age ≤75 years; >75 years 
Time from symptoms onset to 
randomisation 
0–2 hr; >2–4 hr; >4 hr 
Infarct location Anterior; Other  
Previous MI Yes; No 
Sex Male; Female  
Systolic blood pressure 
<100 mmHg; 100–139 mmHg; 
140–159 mmHg; ≥160 mmHg 
Killip class I; II–III 
Hypertension Yes; No  
Diabetes Yes; No  
Previous CABG Yes; No  
Previous PCI Yes; No  
Country Each country separately 
Weight  <60 kg; ≥60–70 kg; ≥70–80 kg; ≥80–90 kg; ≥
90 kg 
Transferred Transferred/ not transferred to Cath lab 
 
A Fisher’s Exact test (in each subgroup) comparing the 2 treatments groups will be 
performed. Also the between group comparison will be done by presenting the 
relative risk with an asymptotic 95% confidence interval (two-sided).  
 
4.8 CONCOMITANT MEDICATIONS 
The number of subjects in each study group who have taken concomitant 
medications during hospitalization (1. during cath lab 2. after cath lab) will be 
reported. The percentage of subjects will be calculated with respect to the number 
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of subjects with non-missing information for that particular item. A Fisher’s Exact 
test will be used to assess potential treatment differences, p-values will be 
presented. 
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APPENDIX A 
Mock Summary Data Tables 
 
Will be added in a next version. 
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2. LIST OF ABBREVIATIONS 
Include a list of all abbreviations used in the TSAP  
Term Definition / description 
AE Adverse event 
CABG Coronary Artery Bypass Grafting 
CCU Coronary Care Unit 
CHF Congestive Heart Failure 
CTP Clinical Trial Protocol 
ECG Electrocardiogram 
EMD Electro-Mechanical Dissociation 
FAS Full analysis set 
rFAS randomised full analysis set 
ICH International Conference on Harmonisation 
ICU Intensive Care Unit 
ITT Intention-To-Treat 
rITT randomised Intention-To-Treat 
IVRS Interactive voice response 
MedDRA Medical Dictionary for Regulatory Activities 
MID Minimal important difference 
mmHg millimetre of mercury 
PCI Percutaneous Coronary Intervention 
PPS Per protocol set 
PT Preferred term 
Q1 Lower quartile 
Q3 Upper quartile 
SAS® a software provided by SAS Institute Inc  
SD Standard deviation 
SOC System organ class 
TSAP Trial statistical analysis plan 
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3. INTRODUCTION 
As per ICH E9, the purpose of this document is to provide a more technical and detailed 
elaboration of the principal features of the analysis described in the protocol, and to include 
detailed procedures for executing the statistical analysis of the primary and secondary 
variables and other data. 
This TSAP assumes familiarity with the Clinical Trial Protocol (CTP), including Protocol 
Amendments. In particular, the TSAP is based on the planned analysis specification as 
written in CTP Section 7 “Statistical Methods and Determination of Sample Size”. Therefore, 
TSAP readers may consult the CTP for more background information on the study, e.g., on 
study objectives, study design and population, treatments, definition of measurements and 
variables, planning of sample size, randomisation. 
SAS® Version 9.22 and R version 2.14.1 will be used for all analyses. 
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4. CHANGES IN THE PLANNED ANALYSIS OF THE STUDY 
In order to adequately deal with CTP amendment 2, in which the dose of Tenecteplase was 
changed for the elderly patients, some imputations will be foreseen to analyse the data (cf. 
Section 6.6). 
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5. ENDPOINTS 
5.1 PRIMARY ENDPOINT 
The primary endpoint is all cause death and shock and CHF and reinfarction at day 30. 
5.2 SECONDARY ENDPOINTS 
5.2.1 Key secondary endpoints  
The following observations are considered as endpoints evaluating the efficacy and 
will be assessed at day 30. They are ordered according to medical importance in the 
indication acute myocardial infarction. 
• All cause mortality 
• Cardiac mortality 
• Cardiogenic shock 
• Congestive heart failure (CHF) 
• Recurrent myocardial infarction (reinfarction) 
• All cause death and shock 
• All cause death and shock and reinfarction 
• All cause death and shock and CHF 
• Rehospitalisation for cardiac reasons 
• Rehospitalisation for non-cardiac reasons 
• Serious repeat target vessel revascularization 
The following observations are considered as endpoints evaluating the safety and 
will be assessed at 30 days. They are ordered according to medical importance in the 
indication acute myocardial infarction. 
• Total fatal stroke 
• Total disabling stroke 
• Total non-disabling stroke 
• Intracranial haemorrhage 
• Ischaemic stroke 
• Total stroke (all types) 
• Major non-intracranial bleeds including blood transfusions 
• Minor non-intracranial bleeds 
• Total non-intracranial bleeds 
• Serious resuscitated ventricular fibrillation 
• Serious resuscitated ventricular fibrillation in association during with invasive 
procedures (occurring at any time during cath / and urgent/elective PCI)  
The following observations are considered as endpoints evaluating both efficacy and 
safety and will be assessed at 30 days. 
• All cause death and non-fatal stroke 
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• All cause death and shock and CHF and reinfarction and disabling stroke 
5.2.2 (Other) Secondary endpoints 
Not applicable. 
5.3 FURTHER ENDPOINTS 
Evaluations within 30 days 
• Duration of stay in CCU/ICU 
• Duration of initial stay in hospital 
• Duration of rehospitalisation started until and including day 30 
• Coronary perfusion pre-/post-PCI 
Evaluations at 1 year 
• All-cause mortality 
• Rehospitalisation (cause of rehospitalisation) 
ECG-based evaluations  
• Successful reperfusion (ST-segment resolution 90 min after injection of tenecteplase; 30-
min post-PCI ST-segment resolution in Group B) 
• Incidence of aborted myocardial infarction (in both groups) 
• Need for rescue PCI/revascularisation (as determined by investigator & central 
adjudication) in Group A 
Further details are available in the appended ECG Substudy Statistical Analysis Plan. 
5.4 OTHER VARIABLES 
Additional serious in-hospital events 
• Major arrhythmias 
• EMD 
• Cardiac rupture 
• Acute ventricular septum defect  
• Acute mitral regurgitation 
• Pericarditis 
• Tamponade 
• Sustained hypotension 
• Recurrent myocardial ischemia 
• Abrupt vessel closure 
• Coronary arterial dissection 
• Hypersensitivity 
• Anaphylactoid reaction 
• Thrombocytopenia  
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• Drop of haemoglobin > 2g/L 
Additional revascularization procedures 
• PCI (after study PCI) 
• CABG (after study catheterisation / study PCI) 
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6. GENERAL ANALYSIS DEFINITIONS 
6.1 TREATMENTS 
Patients are randomised to one of two treatment groups: 
A. Tenecteplase + enoxaparin + clopidogrel (experimental, Group A) 
B. Primary PCI according to local standards (control, Group B) 
6.2 IMPORTANT PROTOCOL VIOLATIONS 
Table 6.2: 1 Important protocol violations 
Category/
Code 
Description Example/Comment Excluded 
from 
A  Entrance criteria not met   
 A1 Inclusion criteria not met  Inclusion criteria not met as specified in the 
protocol. 
None 
 A2 Exclusion criteria not met 
(excluding excl. criterion  20) 
Exclusion criteria not met as specified in the 
protocol 
None 
 A3 Exclusion criterion 20 not met Previous enrolment in this study All 
B  Informed consent   
 B1 no validated informed consent  All 
 B2 Informed consent withdrawn  None 
 B3 Informed consent too late Informed consent occurred after 
randomisation, agreement to use  all data 
None 
 
6.3 PATIENT SETS ANALYSED 
Due to the nature of the study (pre-hospital setting) two populations will be analysed in the 
following order: 
• Full analysis set (FAS): All consented patients either randomised by IVRS or 
treated by the investigator 
Subjects will be analysed according to the treatment group to which they were 
randomised by IVRS or treated by the investigator in the absence of IVRS 
randomisation, irrespective of which study treatment was given or if any study 
treatment was received. This population includes all patients randomised by IVRS 
and/or treated in the absence of IVRS randomisation and for whom informed consent 
was obtained.  This population is also referred to as the intention-to-treat population 
(ITT). 
• Randomised full analysis set (rFAS): All consented patients randomised by IVRS 
Subjects will be analysed according to the treatment group to which they were 
randomised by IVRS, irrespective of which study treatment was given or if any study 
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treatment was received. This population includes all patients randomised by IVRS and 
for whom informed consent was obtained. This population is also referred to as the 
IVRS- randomised intention-to-treat set (rITT). 
 
Post-hoc analyses can be performed on a per protocol set and as treated set if deemed useful. 
Table 6.3: 1 Patient sets analysed 
   
Class of endpoint  FAS rFAS 
Primary and key secondary endpoints   D D 
(other) Secondary and further endpoints   D D 
Safety endpoints   D D 
Demographic/baseline endpoints  D D 
 
6.4 SUBGROUPS 
Subgroup analyses will be done for the primary endpoint, 30-day overall and cardiac 
mortality, shock and recurrent myocardial infarction only. For the timing of randomisation 
subgroup, also the endpoints total stroke, ICH and major non-cerebral bleeds will be 
analysed.  
A test for interaction between subgroup and treatment group will be performed. 
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Table 6.4: 1 Subgroups 
Age  <75 years; ≥75 years 
Age Quartiles of age 
Time from symptom onset to 
randomisation 
0–<1 hr; ≥1–<2 hrs; ≥2hrs 
Time from symptom onset to 
randomisation 
<2 hr; ≥2 hrs 
Infarct location Anterior; Other  
Sex Male; Female  
Systolic blood pressure 
<100 mmHg; 100–139 mmHg; 
140–159 mmHg; ≥160 mmHg 
Killip class I; II–IV 
Hypertension Yes; No  
Diabetes Yes; No  
Weight <60 kg; ≥60–90 kg; ≥90 kg 
Place of randomisation ambulance/ community hospital 
Q-wave With/without new Q-waves (for index MI) at baseline 
TIMI risk score <5; ≥ 5 
Time of randomisation Before / after protocol amendment 2 
 
6.5 POOLING OF CENTRES 
This section is not applicable because centre/country is not included in the statistical model.  
6.6 HANDLING OF MISSING DATA AND OUTLIERS 
Best efforts will be made to collect complete data for the clinical endpoints of interest, 
regardless of whether or not the subject received study drug. 
In order to minimize bias and take all randomised patients into the analysis when the 
proportion of missing data is larger than 1%, a multiple imputation analysis will be 
performed. Reflecting the two different analyses that are planned (see Section 7.4 and Section 
7.5), also two different multiple imputation schemes will be applied. In both cases, 100 
imputations will be performed. The imputation will be done partly in R using the aregImpute 
function in the Hmisc package, cf. reference (2), and partly in SAS. A seed value of 12345 is 
used in both software packages.  
6.6.1 Standard FAS analysis 
The imputation will be done in two parts for different kind of analyses (binary outcomes and 
survival outcomes). In a first part (for the analysis of binary outcomes), the baseline 
covariates age, sex, assigned treatment, body weight, infarct location (anterior or other), 
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previous infarction, Killip class, heart rate, systolic blood pressure and time from symptom 
onset to randomisation, hypertension, diabetes, place of randomisation, Q-wave, TIMI risk 
score together with all single efficacy and safety endpoints will be imputed using the 
aregImpute function. For mortality, the variables cardiac and non-cardiac mortality instead of 
overall mortality will be used. In case of computational problems, primarily 5 times different 
seed values will be used augmenting the seed number by 1 (12345 to 12349). If 
computational problems persist, the endpoint with the fewest number of overall events is 
deleted from the imputation scheme and handled separately later on. In case there are several 
variables with the same small number of events, the variable which comes first in the 
alphabetical order will be omitted first. The same procedure with at most 5 random seeds is 
tried again with one variable less in the imputation scheme. This process is iterated until a 
successful multiple imputation has been obtained. The endpoint(s) that has (have) been 
omitted from the imputation scheme will be imputed by a random draw from a binary with a 
probability of success equal to the maximum of the observed event rate or 0.0001 stratified 
by assigned treatment, sex and age (<75; ≥75 years old). Combined endpoints will be 
constructed based on the imputed single endpoints. 
In a second part (for the analysis of survival outcomes), the time to variables and 
corresponding censor indicator variables (mortality (cardiac and non-cardiac), shock, 
reinfarction, CHF, ICH, major bleed) for patients without any information on these outcomes 
(for instance patients with consent withdrawn and no use of available data allowed) will be 
imputed by selecting their outcomes from a patient with this information available. The 
imputed outcomes will be selected at random from a patient matched on assigned treatment, 
sex and age (<75 or ≥75 years old).  
A similar approach will be performed for the rFAS population. 
6.6.2 Modified FAS analysis 
The same procedure as for the standard FAS analysis will be employed, but before the 
imputation process all single efficacy and safety endpoints of the elderly patients (≥75 years 
old) randomised to experimental arm before protocol amendment 2 will be set to missing.  
A similar approach will be performed for the rFAS population. 
 
6.7 BASELINE, TIME WINDOWS AND CALCULATED VISITS 
Days to a particular event are calculated as day of the event minus day of randomisation plus 
one. 
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7. PLANNED ANALYSIS 
For the analysis of the efficacy and safety endpoints; two analyses will be performed: a 
standard FAS analysis and a modified FAS analysis. For the standard FAS analysis, a 
complete case analysis will be performed in case the proportion missing data is less than 1%, 
otherwise an analysis using multiple imputations will be performed for the standard FAS 
analysis. For the modified FAS analysis, an analysis with multiple imputations in which the 
outcomes in the elderly patients in the experimental group before protocol amendment 2 were 
set to missing will be performed. The standard FAS analysis is considered to be the primary 
analysis and the modified FAS analysis a sensitivity analysis. PROC MIANALYZE will be 
used to combine the results of all imputed analyses. 
Similarly a standard rFAS and modified rFAS analysis will be performed. 
Other explorative analyses such as but not limited to investigating the influence of PCI 
related delay times may be performed. 
7.1 DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS 
For the continuous variables, the mean, standard deviation (SD), median, and range will be 
reported in each treatment group and a t-test or Wilcoxon test will be used, whichever is 
appropriate.  For the discrete variables, the number of subjects in each category and the 
percentage with respect to the number of subjects with non-missing information for that item 
will be reported in each treatment group. A chi-square test for an r x 2 contingency table will 
be performed for all categorical variables. 
P-values for baseline characteristics will be calculated only for descriptive purposes. 
7.2 CONCOMITANT DISEASES AND MEDICATION 
The number of subjects in each study group who have taken concomitant medications during 
hospitalization (1. during cath lab; 2. after cath lab) will be reported. The percentage of 
subjects will be calculated with respect to the number of subjects with non-missing 
information for that particular item. A Fisher’s Exact test will be used to assess potential 
treatment differences, p-values will be presented. 
7.3 TREATMENT COMPLIANCE 
Only descriptive statistics are planned for this section of the report. 
7.4 PRIMARY ENDPOINT 
The primary efficacy endpoint will be analysed by presenting the event rates and the 95% 
confidence intervals (two-sided) separately for each treatment group. In addition, the two 
treatment groups will be compared using a working Poisson regression model, see reference 
(3). Also the between-group comparison will be done by presenting the relative risk with a 
95% confidence interval (two-sided).   
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As secondary analysis, a covariate adjusted working Poisson regression model will be fitted. 
Covariates to be included (forced) in the model are treatment group, sex, age, body weight, 
infarct location (anterior or other), previous infarction, Killip class, heart rate, systolic blood 
pressure and time from symptom onset to randomisation. The relative risk for the treatment 
effect together with a 95% confidence interval (two-sided) will be reported. 
7.5 SECONDARY ENDPOINTS 
7.5.1 Key secondary endpoints 
The single and composite efficacy and safety endpoints will be analysed by presenting the 
event rates and the 95% confidence intervals (two-sided) separately for each treatment group. 
In addition, the two treatment groups will be compared by a modified Poisson regression, see 
reference (3). Also the between-group comparison will be done by presenting the relative risk 
with a 95% confidence interval (two-sided). 
In case there are no events in a particular treatment group (before imputation), an artificial 
observation in each cell (treatment group by event) with weight 0.5 will be added in order to 
estimate a relative risk. 
As secondary analysis, a covariate adjusted working Poisson regression model will be fitted 
for two important key secondary endpoints, i.e. all cause 30-day mortality or all cause 30-day 
mortality and cardiogenic shock, as dependent variable and treatment group as independent 
variable. Additionally, possible important predictors such as sex, age, body weight, infarct 
location (anterior or other), previous infarction, Killip class, heart rate, systolic blood 
pressure and time from symptom onset to randomisation will be used (forced into the model). 
The relative risk for the treatment effect together with a 95% confidence interval (two-sided) 
will be reported. 
In addition, a Kaplan-Meier plot for all-cause mortality, cardiac mortality, cardiogenic shock, 
CHF and reinfarction will be created. A logrank test will be performed to test for potential 
differences between the treatment groups. 
Furthermore a time-to-first-event analysis of the combined endpoint all-cause death, shock, 
CHF and reinfarction will be performed. A Kaplan-Meier plot will be produced and a logrank 
test will be performed. 
Finally, a weighted time-to-event analysis of the combined endpoint all-cause death, shock, 
CHF and reinfarction will be performed. The methodology described in reference (1) will be 
applied. An interpretation of the methodology is described in reference (4). The same weights 
will be applied, that is 1.0 for death, 0.5 shock, 0.3 CHF and 0.2 reinfarction. This analysis 
efficiently incorporates the differential value of all events in each patient in contrast to the 
more commonly applied time-to-first-event analysis. The trade-off with safety events (i.e., 
intracranial haemorrhage and major systemic bleeding) will also be examined. The same 
weights as described in reference (1) will be applied. That is, 0.48 for intracranial 
haemorrhage and 0.28 for major bleeds. 
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Due to the explorative nature of the trial no confirmatory statistical hypothesis test is pre-
specified, hence it should be noted that the individual endpoints have a different probability 
of demonstrating a potential benefit for one of the treatment groups. The power to show a 
significant difference depends on the incidence rates. Based on the anticipated incidence rates 
(given between brackets) for the different endpoints, the efficacy endpoints are ordered as 
follows for showing any potential significant difference of a given size between the two 
treatment groups.  
• Rehospitalisation for cardiac reasons (2%) 
• Rehospitalisation for non-cardiac reasons (2%) 
• Cardiogenic shock (3%) 
• Recurrent myocardial infarction (reinfarction) (3%) 
• All cause mortality (4%) 
• All cause death and shock (5.5%) 
• Congestive heart failure (CHF) (6%) 
• All cause death and shock and CHF (11%) 
• All cause death and shock and reinfarction (13%) 
• All cause death and shock and CHF and reinfarction (15%) 
 
The safety endpoints are ordered as follows for showing any potential significant difference 
of a given size between the two treatment groups.  
• Total disabling stroke (0.4 %) 
• Total non-disabling stroke (0.4%) 
• Ischaemic stroke (0.7%) 
• Total fatal stroke (0.8 %) 
• Intracranial haemorrhage (0.9%) 
• Resuscitated ventricular fibrillation (<1 %) 
• Total stroke (1.5 %) 
• Blood transfusions (3%) 
• Major non-intracranial bleeds (4 %)  
• Repeat target vessel revascularization (4%) 
• Minor non-intracranial bleeds (20 %)  
• Total non-intracranial bleeds (24 %) 
Furthermore, p-values are given for descriptive purposes only. Due to the numerous 
endpoints of interest, one should be aware of the multiple testing problem (control of the type 
I error). Findings should be interpreted in terms of generating hypotheses for future trials. 
7.5.2 (Other) Secondary endpoints 
This section is not applicable as no other secondary endpoint has been specified in the 
protocol. 
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7.6 FURTHER ENDPOINTS 
Evaluations within 30 days  
The different durations will be summarized with descriptive statistics (median, quartiles, 
minimum and maximum) and compared between the two treatment groups by a Wilcoxon 
test. 
The analyses of the duration of stay in CCU/ICU and the duration of initial stay in hospital 
will be performed for in-hospital survivors only and for all patients including those that died 
in-hospital. For the latter case, the durations for the patients who died in-hospital will be 
imputed by the maximum of the durations observed among the survivors up to day 30. 
The analysis of the duration of rehospitalisation started until and including day 30 will be 
performed for patients that had a rehospitalisation up to day 30. 
Coronary perfusion pre-/post-PCI will be summarized by the number of subjects in each 
category and the percentage with respect to the number of subjects with non-missing 
information for that item will be reported in each treatment group.  A chi-square test for an 4 
x 2 contingency table will be performed. 
Evaluations at 1 year 
Analyses of the 1-year evaluations will be performed after the 1-year results are available for 
all patients. Time-to-event analyses (Kaplan-Meier) will be performed for all-cause mortality. 
The time to death from randomisation (in days) will be used as time variable. In case no event 
is present, the last time the patient was seen will be used as censoring time. The frequency 
and causes of rehospitalisation will be analysed descriptively. 
ECG-based evaluations  
Further details on the ECG-based evaluations can be found in the appended Statistical 
Analysis Plan for the ECG Sub-study. These endpoints will be analysed under the 
responsibility of Prof. P. W. Armstrong, University of Alberta, Edmonton, Canada. 
7.7 EXTENT OF EXPOSURE 
Not applicable 
7.8 SAFETY ANALYSIS 
7.8.1 Adverse events 
Unless otherwise specified, the analyses of adverse events will be descriptive in nature. All 
analyses of AEs will be based on the number of patients with AEs.  
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The frequency of patients with adverse events will be summarised by treatment, primary 
system organ class (SOC) and preferred term (PT) (MedDRA levels to be displayed in the 
tables).  
The system organ classes will be sorted according to the standard sort order specified by 
EMEA, preferred terms will be sorted by frequency (within system organ class). 
7.8.2 Laboratory data 
Haematology values (first available values and values at discharge or day 4) and cardiac 
enzymes will be described descriptively only by treatment group.  
7.8.3 Vital signs 
Only descriptive statistics are planned for this section of the report. 
7.8.4 ECG 
The ECG metrics will be assessed by the core laboratory at the Canadian VIGOUR Centre at 
the University of Alberta, Edmonton, Canada under the direction of Prof. P. W. Armstrong 
7.8.5 Others 
For additional in-hospital events and additional revascularization procedures, the number of 
subjects in each category and the corresponding percentage for that item will be reported in 
each treatment group. Fisher’s Exact test will be performed. 
7.9  HEALTH-ECONOMIC ANALYSIS 
The health-economic analysis will be considered in a separate health-economic analysis plan. 
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9. ADDITIONAL SECTIONS 
Not applicable as no additional information is needed. 
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10. HISTORY TABLE 
Table 10: 1 History table 
Version Date 
(DD-Mmm-YYYY) 
Author Sections 
changed 
Brief description of change 
Final 14-Dec-2012 Erich Bluhmki None This is the final TSAP without any 
modification 
 
2c. Summary of changes 
 
 
 
 
History of  statistical analysis plan 
There is  one officially signed statistical analysis plan (SAP) made  before data base lock (24 
December 2012). The major changes mentioned below are those compared toa first rough draft SAP 
from 6 March, 2008. 
‐ Updated analysis sets 
‐ Added efficacy endpoint "cardiac mortality" 
‐ Added safety endpoint " Resuscitated ventricular fibrillation in association  with invasive 
procedures (occurring at any time during cath / and urgent/elective PCI)" 
‐ Handling of missing data with multiple imputation in case > 1 % missing data is observed 
‐ Added a modified analysis in order to take protocol amendment into account  
‐ Reporting relative risks from a Poisson regression model with robust variance error instead of 
odd ratio's from a logistic regression analysis  
‐ Updated list of subgroups 
‐ Added weighted time‐to‐event analyses 
